var title_f13_42_13984="Poole tip suction device";
var content_f13_42_13984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Poole tip suction device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This advantage of this device is that it limits adherence to tissue surfaces.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13984=[""].join("\n");
var outline_f13_42_13984=null;
var title_f13_42_13985="Laron syndrome";
var content_f13_42_13985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laron syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of a five-year-old girl with Laron syndrome. Note dwarfism, obesity, and typical facial features.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laron Z. Biologic and clinical aspects of molecular defects along the growth hormone-insulin-like growth factor I axis. In: Pediatric Endocrinology: Mechanisms, Manifestations, and Management, 1st ed, Eugster E, Pescovitz O (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13985=[""].join("\n");
var outline_f13_42_13985=null;
var title_f13_42_13986="Patient information: Thyroiditis (The Basics)";
var content_f13_42_13986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86462\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"         Thyroid and parathyroid glands",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/58/13219\">",
"         Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/54/3938\">",
"         Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/50/5922\">",
"         Patient information: Thyroiditis after pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/6/3172\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/54/15203\">",
"         Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Thyroiditis (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H100339859\">",
"      <span class=\"h1\">",
"       What is thyroiditis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Thyroiditis is a condition that happens when a gland in the neck called the thyroid gets inflamed (",
"      <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"       figure 1",
"      </a>",
"      ). This gland makes thyroid hormone, which controls how the body uses and stores energy.",
"     </p>",
"     <p>",
"      If you have thyroiditis, your thyroid gland leaks large amounts of thyroid hormone into your bloodstream. This causes a condition called HYPERthyroidism. That is the medical term for too much thyroid hormone. Hyperthyroidism lasts only until the thyroid hormone stored in your gland is used up.",
"     </p>",
"     <p>",
"      After that happens, you may not have enough thyroid hormone in your bloodstream. This causes a condition called HYPOthyroidism. That is the medical term for too little thyroid hormone. But once the inflammation goes away and you thyroid gland heals, it will start to make thyroid hormone again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100339892\">",
"      <span class=\"h1\">",
"       What causes thyroiditis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many different things can cause thyroiditis, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems with the body&rsquo;s infection-fighting system, called the &ldquo;immune system.&rdquo; If your immune system attacks healthy cells, including cells in your thyroid, it is called an &ldquo;autoimmune response.&rdquo;",
"       </li>",
"       <li>",
"        Pregnancy",
"       </li>",
"       <li>",
"        Medicines or radiation",
"       </li>",
"       <li>",
"        Infections",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100339909\">",
"      <span class=\"h1\">",
"       What are the symptoms of thyroiditis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some types of thyroiditis cause the thyroid gland to swell. Sometimes, this can also cause pain in the neck that can spread to the jaw and ears.",
"     </p>",
"     <p>",
"      Most people with thyroiditis first have symptoms of hyperthyroidism. Common symptoms of hyperthyroidism include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling weak or tired",
"       </li>",
"       <li>",
"        Losing weight, even when eating normally",
"       </li>",
"       <li>",
"        Having a fast or uneven heartbeat",
"       </li>",
"       <li>",
"        Sweating a lot and having trouble dealing with hot weather",
"       </li>",
"       <li>",
"        Feeling worried",
"       </li>",
"       <li>",
"        Trembling",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The symptoms of hyperthyroidism might last for up to 6 to 8 weeks. Then, people with thyroiditis might have symptoms of hypothyroidism, which can last for 2 to 8 weeks. Common symptoms of hypothyroidism include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having no energy",
"       </li>",
"       <li>",
"        Feeling cold",
"       </li>",
"       <li>",
"        Trouble having bowel movements (constipation)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In most people with thyroiditis, thyroid hormone levels return to normal within 6 to 8 months.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100339924\">",
"      <span class=\"h1\">",
"       Is there a test for thyroiditis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. You will need blood tests, called thyroid function tests.",
"     </p>",
"     <p>",
"      Your doctor might also order other tests. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Thyroid scan - For this test, you get a pill or shot with a small amount of a radioactive substance. Then a special camera takes pictures of your thyroid.",
"       </li>",
"       <li>",
"        Thyroid ultrasound &ndash; This test uses sound waves to create pictures of the thyroid.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100339939\">",
"      <span class=\"h1\">",
"       How is thyroiditis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on your symptoms and what caused your thyroiditis. If you do not have symptoms, you might not need any treatment. But your doctor will check your thyroid function every so often to be sure it returns to normal.",
"     </p>",
"     <p>",
"      If you have symptoms, your doctor might prescribe medicines, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Thyroid hormone pills",
"       </li>",
"       <li>",
"        Pain relievers such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;)",
"       </li>",
"       <li>",
"        Medicines called &ldquo;beta blockers,&rdquo; which slow down the heart rate",
"       </li>",
"       <li>",
"        Antibiotics",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100339954\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/58/13219?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/50/5922?source=see_link\">",
"       Patient information: Thyroiditis after pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/42/13986?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86462 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13986=[""].join("\n");
var outline_f13_42_13986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100339859\">",
"      What is thyroiditis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100339892\">",
"      What causes thyroiditis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100339909\">",
"      What are the symptoms of thyroiditis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100339924\">",
"      Is there a test for thyroiditis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100339939\">",
"      How is thyroiditis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100339954\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"      Thyroid and parathyroid glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/58/13219?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/50/5922?source=related_link\">",
"      Patient information: Thyroiditis after pregnancy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_42_13987="Multiple healing rib fractures in an abused infant";
var content_f13_42_13987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Multiple healing rib fractures in an abused infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple healing rib fractures (arrows) in an infant who also had an acute subdural hematoma, linear parietal skull fracture, and skin bruising.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cindy Christian, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13987=[""].join("\n");
var outline_f13_42_13987=null;
var title_f13_42_13988="Azithromycin (ophthalmic): Patient drug information";
var content_f13_42_13988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azithromycin (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/11/21683?source=see_link\">",
"     see \"Azithromycin (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/2/10275?source=see_link\">",
"     see \"Azithromycin (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7983203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AzaSite&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azithromycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3434951",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Turn bottle with lid on upside down and shake 1 time before each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699144",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After opening, store at room temperature. Throw away after 14 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10892 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13988=[""].join("\n");
var outline_f13_42_13988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983203\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030907\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030906\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030911\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030912\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030914\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030909\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030910\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030915\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030916\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/11/21683?source=related_link\">",
"      Azithromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/2/10275?source=related_link\">",
"      Azithromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=related_link\">",
"      Azithromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=related_link\">",
"      Azithromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/3/6200?source=related_link\">",
"      Azithromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_42_13989="Promethazine and codeine: Patient drug information";
var content_f13_42_13989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Promethazine and codeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/10/29862?source=see_link\">",
"     see \"Promethazine and codeine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/45/26325?source=see_link\">",
"     see \"Promethazine and codeine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child younger than 6 years of age. Very bad effects may happen. Follow how to use very closely and check all drugs with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a child younger than 6 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to codeine, promethazine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11293 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-FDE34C00CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13989=[""].join("\n");
var outline_f13_42_13989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029574\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029576\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029575\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029580\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029581\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029583\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029578\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029579\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029584\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029585\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/10/29862?source=related_link\">",
"      Promethazine and codeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/45/26325?source=related_link\">",
"      Promethazine and codeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_42_13990="Ganciclovir (systemic): Pediatric drug information";
var content_f13_42_13990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ganciclovir (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/3/24630?source=see_link\">",
"    see \"Ganciclovir (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/18/31012?source=see_link\">",
"    see \"Ganciclovir (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8106920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8106925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytovene&reg;-IV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8106926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cytovene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"     <b>",
"      Congenital CMV (symptomatic; CNS-disease); treatment (independent of HIV status):",
"     </b>",
"     6 mg/kg/dose every 12 hours for 6 weeks; if neonate diagnosed as HIV-positive, a longer duration of therapy may be considered (CDC, 2009; Redbook, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/3/24630?source=see_link\">",
"      see \"Ganciclovir (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      CMV infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Congenital CMV (symptomatic; CNS-disease); treatment (independent of HIV status): 6 mg/kg/dose  every 12 hours for 6 weeks; if neonate diagnosed as HIV-positive a longer duration of therapy may be considered (CDC, 2009; Redbook, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CNS infection, treatment (HIV-exposed/-positive): Infants and Children: 5 mg/kg/dose every 12 hours plus foscarnet; continue until symptoms improve, followed by chronic suppression (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Disseminated disease and retinitis, treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &ge;3 months and Children: 5 mg/kg/dose every 12 hours for 14-21 days; may be increased to 7.5 mg/kg/dose every 12 hours (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adults: Manufacturer&rsquo;s labeling: 5 mg/kg/dose every 12 hours for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &ge; 3 months and Children: 5 mg/kg/dose as a single daily dose for 5-7 days/week (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adults: Manufacturer&rsquo;s labeling: 5 mg/kg/dose as a single daily dose for 7 days/week or 6 mg/kg/dose for 5 days/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Secondary prevention in HIV-exposed/-infected patients: Infants and Children: 5 mg/kg/dose once daily (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prevention in transplant recipients: Children and Adults: Initial: 5 mg/kg/dose  every 12 hours for 1-2 weeks, followed by 5 mg/kg/dose once daily 7 days/week or 6 mg/kg/dose once daily 5 days/week for 100 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prevention in lung/heart-lung transplant patients (CMV-positive donor with CMV-positive recipient): Children and Adults: 6 mg/kg/dose once daily for 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Other CMV infections: Children and Adults: Initial: 5 mg/kg/dose every 12 hours for 14-21 days; maintenance therapy: 5 mg/kg/dose once daily for 7 days/week or 6 mg/kg/dose once daily for 5 days/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Varicella zoster; progressive outer retinal necrosis:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: 5 mg/kg/dose every 12 hours plus systemic foscarnet and intravitreal ganciclovir or foscarnet (CDC, 2009; Kaplan, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Induction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-69 mL/minute: Administer 2.5 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-49 mL/minute: Administer 2.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-24 mL/minute: Administer 1.25 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 1.25 mg/kg/dose 3 times/week following hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-69 mL/minute: Administer 2.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-49 mL/minute: Administer 1.25 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-24 mL/minute: Administer 0.625 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 0.625 mg/kg/dose 3 times/week following hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50%): CMV Infection: I.V.: Induction: 1.25 mg/kg every 48-72 hours; Maintenance: 0.625 mg/kg every 48-72 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis (PD): Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment: CMV infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVH: I.V.: Induction: 2.5 mg/kg every 24 hours; Maintenance: 1.25 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVHD/CVVHDF: I.V.: Induction: 2.5 mg/kg every 12 hours; Maintenance: 2.5 mg/kg every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8107058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytovene&reg;-IV: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8106928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Follow same precautions utilized with antineoplastic agents when preparing and administering ganciclovir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Reconstitute with SWI",
"     <b>",
"      not",
"     </b>",
"     bacteriostatic water because parabens may cause precipitation; further dilute to a final concentration not to exceed 10 mg/mL. Administer by slow I.V. infusion over at least 1 hour; too rapid infusion can cause increased toxicity and excessive plasma levels. Flush line well with NS before and after administration. Do not administer I.M. or SubQ; due to high pH, may cause severe tissue irritation.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8106989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with paraben preserved bacteriostatic water for injection (may cause precipitation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, anidulafungin, caspofungin, cisplatin, cyclophosphamide, docetaxel, doxorubicin liposome, enalaprilat, etoposide phosphate, filgrastim, fluconazole, granisetron, linezolid, melphalan, methotrexate, paclitaxel, pemetrexed, propofol, remifentanil, teniposide, thiotepa.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amifostine, amsacrine, aztreonam, cefepime, cytarabine, doxorubicin, fludarabine, foscarnet, gemcitabine, ondansetron, piperacillin/tazobactam, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aldesleukin, cisatracurium, sargramostim, tacrolimus.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10503287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intact vials should be stored  at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Reconstituted solution is stable for 12 hours at room temperature; do not refrigerate; diluted I.V. ganciclovir solutions in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS with a concentration &le;10 mg/mL are stable for 28 days under refrigeration; however, the manufacturer recommends use within 24 hours due to SWI reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10503162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with AIDS (FDA approved in adults); prevention of CMV disease in transplant recipients at risk for CMV (FDA approved in adults); has also been used in CMV GI infections and pneumonitis; ganciclovir also has antiviral activity against herpes simplex virus types 1 and 2",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8106922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytovene&reg; may be confused with Cytosar&reg;, Cytosar-U",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ganciclovir may be confused with acyclovir",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8106966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, neutropenia with ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Retinal detachment (relationship to ganciclovir not established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction (including anaphylaxis), alopecia, arrhythmia, bronchospasm, cardiac arrest, cataracts, cholestasis, coma, dyspnea, edema, encephalopathy, exfoliative dermatitis, extrapyramidal symptoms, hepatitis, hepatic failure, pancreatitis, pancytopenia, pulmonary fibrosis, psychosis, rhabdomyolysis, seizure, alopecia, urticaria, eosinophilia, hemorrhage, Stevens-Johnson syndrome, torsade de pointes, renal failure, SIADH, visual loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10507575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ganciclovir, acyclovir, or any component; absolute neutrophil count &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10501472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment. Use with extreme caution in children since long-term safety has not been determined and due to ganciclovir's potential for long-term carcinogenic and adverse reporductive effects.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10503163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Granulocytopenia (neutropenia), anemia, and thrombocytopenia may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Dosage adjustment or interruption of therapy may be necessary in patients with neutropenia, anemia, and/or thrombocytopenia; ganciclovir should not be administered if ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or if platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Animal studies have demonstrated carcinogenic and teratogenic effects, and inhibition of spermatogenesis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; due to its mutagenic potential, contraceptive precautions for female and male patients need to be followed during and for at least 90 days after therapy with the drug; phlebitis may occur at site of infusion; infuse only into veins with adequate blood flow.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8106969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imipenem: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. May increase risk of seizures.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Ganciclovir-Valganciclovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Nucleoside): Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Stavudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8106946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8106947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Animal studies have demonstrated carcinogenic and teratogenic effects, and inhibition of spermatogenesis.",
"     </b>",
"     Female patients should use effective contraception during therapy; male patients should use a barrier contraceptive during and for at least 90 days after therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10503525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, urine output, serum creatinine, ophthalmologic exams, liver enzyme tests, blood pressure, urinalysis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10503288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase; ganciclovir triphosphate competes with deoxyguanosine triphosphate for incorporation into viral DNA and interferes with viral DNA chain elongation resulting in inhibition of viral replication",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10503289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributes to most body fluids, tissues, and organs, including the eyes and brain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 9 months to 12 years: 0.64 &plusmn; 0.22 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 0.74 &plusmn; 0.15 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 1% to 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life (prolonged with impaired renal function):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates 2-49 days of age: 2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 9 months to 12 years: 2.4 &plusmn; 0.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Mean: 2.5-3.6 hours (range: 1.7-5.8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Majority (80% to 99%) excreted as unchanged drug in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: 40% to 50% removed by a 4-hour hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10503526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/18/31012?source=see_link\">",
"      see \"Ganciclovir (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Women of childbearing potential should be advised to use effective contraception during treatment. Men should be advised to practice barrier contraception during and for at least 90 days following treatment with ganciclovir. Mothers should discontinue breast-feeding while on ganciclovir therapy. Ganciclovir is not a cure for CMV retinitis. Regular follow-up ophthalmologic exams are necessary.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10501474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g: 4 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Amir J, Wolf DG, and Levy I, \"Treatment of Symptomatic Congenital Cytomegalovirus Infection With Intravenous Ganciclovir Followed by Long-Term Oral Valganciclovir,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2010, 169(9):1061-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/20232081/pubmed\" id=\"20232081\" target=\"_blank\">",
"        20232081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-216.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fletcher C, Sawchuk R, Chinnock B, et al, &ldquo;Human Pharmacokinetics of the Antiviral Drug DHPG,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1986, 40(3):281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/3017630/pubmed\" id=\"3017630\" target=\"_blank\">",
"        3017630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodrich JM, Bowden RA, Fisher L, et al, \"Ganciclovir Prophylaxis to Prevent Cytomegalovirus Disease After Allogeneic Marrow Transplant,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1993, 118(3):173-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/8380242/pubmed\" id=\"8380242\" target=\"_blank\">",
"        8380242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gudnason T, Belani KK, and Balfour HH Jr, &ldquo;Ganciclovir Treatment of Cytomegalovirus Disease in Immunocompromised Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(7):436-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/2547191/pubmed\" id=\"2547191\" target=\"_blank\">",
"        2547191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merigan TC, Renlund DG, Keay S, et al, \"A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease After Heart Transplantation,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 326(18):1182-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/1313549/pubmed\" id=\"1313549\" target=\"_blank\">",
"        1313549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Group B Streptococcal Infections,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/3.126",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schleiss MR, \"Antiviral Therapy of Congenital Cytomegalovirus Infection,\"",
"      <i>",
"       Semin Pediatr Infect Dis",
"      </i>",
"      , 2005, 16(1):50-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/15685150/pubmed\" id=\"15685150\" target=\"_blank\">",
"        15685150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41:1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/42/13990/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15994 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-59F4F6E9F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13990=[""].join("\n");
var outline_f13_42_13990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106920\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106925\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106926\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501471\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442566\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503504\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107058\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106928\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503524\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106989\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503287\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503162\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106922\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106966\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507575\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501472\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503163\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299387\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106969\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106946\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106947\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503525\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503288\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503289\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503526\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501474\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15994\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15994|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/5/6228?source=related_link\">",
"      Ganciclovir (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41811?source=related_link\">",
"      Ganciclovir (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/58/6052?source=related_link\">",
"      Ganciclovir (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/3/24630?source=related_link\">",
"      Ganciclovir (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/18/31012?source=related_link\">",
"      Ganciclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_42_13991="Keratin in thymoma";
var content_f13_42_13991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunoperoxidase stain for keratin highlights the epithelial cells in thymoma. (Magnification 50x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13991=[""].join("\n");
var outline_f13_42_13991=null;
var title_f13_42_13992="Approach to episiotomy";
var content_f13_42_13992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to episiotomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13992/contributors\">",
"     Julian N Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13992/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13992/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/42/13992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episiotomy refers to a surgical incision of the female perineum performed by the accoucheur at the time of parturition. It is usually performed with scissors when the perineum is stretched and distended, just prior to crowning of the fetal head. The purpose is to increase the diameter of the soft tissue pelvic outlet, thereby preventing perineal lacerations, facilitating delivery, and reducing the time for expulsion of the infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF EPISIOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episiotomy is one of the most common operations performed on women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/1\">",
"     1",
"    </a>",
"    ]. Changing trends in obstetrical practice over time have influenced the decision to perform an episiotomy and resulted in a decreasing prevalence of the procedure (60.9 percent of vaginal deliveries in 1979 versus 24.5 percent in 2004) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of episiotomy is highest in Latin America and lower in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/3\">",
"     3",
"    </a>",
"    ], with reported rates varying widely from 1 percent (Sweden) to 80 percent (Argentina) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to perform an episiotomy appears to be influenced by the type of obstetrical provider. Specifically, private practitioners and faculty providers are more likely than midwives to use this procedure (four-fold and two-fold higher, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Maternal position, parity, and use of epidural anesthesia also appear to play a role in the decision to perform episiotomy. An upright or lateral maternal childbirth position is associated with fewer episiotomies than the supine or lithotomy positions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/9\">",
"     9",
"    </a>",
"    ], while epidural anesthesia and primiparity may increase the incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/6,10,11\">",
"     6,10,11",
"    </a>",
"    ]. Episiotomy is more common with operative than spontaneous vaginal deliveries (71 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RATIONALE FOR EPISIOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purported benefits of episiotomy include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduction in third and fourth degree tears",
"     </li>",
"     <li>",
"      Ease of repair and improved wound healing",
"     </li>",
"     <li>",
"      Preservation of the muscular and fascial support of the pelvic floor",
"     </li>",
"     <li>",
"      Reduction in neonatal trauma, such as with the premature infant (soft cranium) or macrosomic infant (shoulder dystocia)",
"     </li>",
"     <li>",
"      Reduction in dystocia by increasing the diameter of the soft tissue outlet",
"     </li>",
"     <li>",
"      Expedited delivery of fetuses with nonreassuring fetal heart rate tracings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary reason to perform an episiotomy is to prevent a spontaneous, large, irregular laceration of the perineum. It has been argued that a controlled surgical incision is usually easier to repair than a spontaneous laceration. The repair of a surgical incision is also more likely to be anatomically correct, and thus, less likely to result in long-term complications.",
"   </p>",
"   <p>",
"    The role of episiotomy in preventing serious pelvic relaxation has not been adequately evaluated. There is increasing consensus that the median episiotomy is not effective for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link&amp;anchor=H9#H9\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\", section on 'Median episiotomy'",
"    </a>",
"    .) However, mediolateral episiotomy may be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An episiotomy may also be performed to increase the size of the pelvic soft tissue outlet. This may aid in the delivery of a macrosomic or breech infant, and may shorten the time to expulsion if fetal compromise is suspected. If a shoulder dystocia is anticipated, it may be prudent to perform an intentional episiotomy to create more room for the obstetric maneuvers required to relieve the dystocia. Although episiotomy has been advocated to minimize the risk of intraventricular hemorrhage in preterm births, there is no evidence that this intervention is effective on a routine basis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefits of episiotomy need to be weighed against potential adverse effects resulting from this procedure, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extension of the incision, leading to third and fourth degree tears",
"     </li>",
"     <li>",
"      Unsatisfactory anatomic results (eg, skin tags, asymmetry, fistula, narrowing of introitus)",
"     </li>",
"     <li>",
"      Increased blood loss",
"     </li>",
"     <li>",
"      Increased postpartum pain",
"     </li>",
"     <li>",
"      Higher rates of infection and dehiscence",
"     </li>",
"     <li>",
"      Sexual dysfunction",
"     </li>",
"     <li>",
"      Possible increased risk of perineal laceration in subsequent deliveries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risks of these adverse effects are discussed below. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Evidence'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a lack of high-quality evidence upon which to base recommendations for routine episiotomy versus no episiotomy, or make recommendations favoring one approach over another. Studies are often limited by their small size, lack of randomization, absence of suitable controls, and inability to adjust for large variations in operator ability and technique. There are more data comparing the role of routine versus restrictive use of episiotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Episiotomy versus no episiotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of studies of interventions affecting perineal trauma concluded there was good evidence that avoiding routine episiotomy significantly decreased perineal trauma (absolute risk difference -0.23, 95% CI -0.35 to -0.11) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/15\">",
"     15",
"    </a>",
"    ]. This is important since perineal trauma is a causal factor for postpartum pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/16\">",
"     16",
"    </a>",
"    ] and dyspareunia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/17\">",
"     17",
"    </a>",
"    ]. However, there is no direct evidence that use of episiotomy is associated with a higher prevalence of postpartum pain. In some studies, women who gave birth with an intact perineum or had a spontaneous perineal laceration had less pain immediately and three months postpartum than women who underwent episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]; however, others have found no significant difference in postpartum pain between these populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar conflicting data exist regarding sexual function. The possibility of sexual dysfunction appears to be greater when an episiotomy is performed than when it is omitted; however, this effect is of a limited duration. Women with spontaneous tears rather than episiotomy have been reported to have less postpartum pain and earlier resumption of sexual intercourse in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Other studies with long-term follow-up have not found a higher incidence of dyspareunia in women who underwent episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/17,22\">",
"     17,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is equally controversial whether episiotomy results in weaker perineal muscle function over the long-term than no episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/13,18,19,21,23-25\">",
"     13,18,19,21,23-25",
"    </a>",
"    ]. The literature, which largely consists of poorly controlled studies, is difficult to interpret since the timing of episiotomy, surgical technique (median versus mediolateral), and skill of the individual repairing the episiotomy vary significantly. Furthermore, since episiotomy is usually performed when crowning occurs at the introitus, the levator muscle has already been pushed aside, stretched,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    torn. Thus, episiotomy incisions and lacerations primarily cut through only the urogenital diaphragm structures. It is believed that much of the strength in the perineal musculature may be regained over time and with pelvic muscle exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Routine versus restricted use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews have consistently shown that there is no benefit to routine use of episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/3,26\">",
"     3,26",
"    </a>",
"    ]. Therefore, while episiotomy as a routine procedure in all spontaneous vaginal births is",
"    <strong>",
"     not",
"    </strong>",
"    recommended, a restricted approach in appropriate clinical settings is advocated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of randomized trials comparing restrictive use of episiotomy to routine use found that the restricted use resulted in less posterior perineal trauma (relative risk [RR] 0.88, 95% confidence interval [CI] 0.84-0.92), less suturing (RR 0.74, 95% CI 0.71- 0.77), and fewer healing complications (RR 0.69, 95%CI 0.56-0.85), although there was more anterior perineal trauma (RR 1.79, 95% CI 1.55-2.07) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/3\">",
"       3",
"      </a>",
"      ]. Both median and mediolateral episiotomies were included in the trials. There were no differences in the incidence of severe lacerations, dyspareunia, urinary incontinence, and several measures of pain.",
"     </li>",
"     <li>",
"      Another systematic review concluded that there was no evidence that a policy of routine episiotomy resulted in significant reductions in laceration severity, pain, or pelvic organ prolapse compared to a policy of restricted use [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/26\">",
"       26",
"      </a>",
"      ]. A total of 26 randomized controlled trials which assessed outcomes in the first three months postpartum and prospective studies which assessed longer-term outcomes were included in the analysis. A subsequent randomized trial that compared restrictive and routine episiotomy in nulliparas also reported no difference between groups in the rates of urinary or anal incontinence, with follow-up four years postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition, a decision-tree model showed that a policy of routine episiotomy was more costly than restricted performance of the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/28\">",
"       28",
"      </a>",
"      ]. Only procedure related costs up to one month postpartum were considered in the analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, the American College of Obstetricians and Gynecologists support the position of restricted instead of routine use of episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/12\">",
"     12",
"    </a>",
"    ]. Avoidance of routine episiotomy is recommended for both spontaneous and instrumental deliveries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Training courses, audits, presence of a staff leader and episiotomy rate feedback for individual midwives and obstetricians appear to help reduce the use of routine episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate analgesia should be available before performing an episiotomy. Regional anesthesia, such as an epidural block, may have been administered for analgesia during labor and delivery. However, if there is no preexisting analgesia, an appropriate technique should be selected (eg, pudendal nerve block, local field block). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40439?source=see_link\">",
"     \"Pudendal and paracervical block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal time for cutting the episiotomy is unclear. Excessive blood loss can result from making the incision too early, but protection of the maternal perineum may be compromised if it is made too late and the fetal head has already torn perineal muscle and fascia. A reasonable approach is to perform the procedure with the expectation of delivering the fetus within the next three to four contractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Type",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are inadequate data from randomized trials on which to base a recommendation for choosing the type of episiotomy incision. Controlled studies have shown that selective use of mediolateral episiotomy results in a lower rate of third and fourth degree lacerations than median episiotomies. For this reason, the Royal College of Obstetricians and Gynaecologists recommend mediolateral rather than median episiotomy, when episiotomy is clinically indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/30\">",
"     30",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists also state mediolateral episiotomy may be preferable to median episiotomy in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two major types of episiotomy: median and mediolateral, as well as several modifications of these basic types (&ldquo;J&rdquo; incision, &ldquo;T&rdquo; incision, and lateral incision) (",
"    <a class=\"graphic graphic_figure graphicRef70476 \" href=\"UTD.htm?28/27/29119\">",
"     figure 1",
"    </a>",
"    ) and an anterior incision that is only used in women who have undergone female infibulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Other'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34133?source=see_link&amp;anchor=H8#H8\">",
"     \"Female genital cutting (circumcision)\", section on 'Obstetrical issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because precise descriptions of the different types of episiotomy have not been standardized, there can be substantial variations between practitioners in the performance of the same type of episiotomy. In particular, the angle away from midline can vary significantly depending on the practitioner and the degree the perineum is stretched when the incision is made. The depth, length, and angle of the incision appear to be important factors in risk of obstetric anal sphincter injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Median",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median (or midline) episiotomy is the most commonly used technique in the United States. A vertical incision is begun at the fourchette and extended caudally in the midline. The goal is to release any restriction imposed offered by the perineal body, which can sometimes be felt as a band of tissue cephalad and posterior to the vaginal orifice. Therefore, the incision should be directed internally to minimize the amount of perineal skin incised. The anatomical structures involved in the incision include the vaginal epithelium, perineal body, and the junction of the perineal body with the bulbocavernosus muscle in the perineum.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advantages and disadvantages &mdash; The median episiotomy is typically easier to repair than a mediolateral episiotomy or a spontaneous",
"      <span class=\"nowrap\">",
"       vaginal/perineal",
"      </span>",
"      laceration and yields a better cosmetic result [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/33\">",
"       33",
"      </a>",
"      ]. Another purported benefit is that it is associated with less pain postpartum. However, the only randomized trial comparing median to mediolateral episiotomy found",
"      <strong>",
"       no",
"      </strong>",
"      difference in subjective assessment of pain or analgesic requirements [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/33\">",
"       33",
"      </a>",
"      ]. In addition, there were no differences in patient reports of dyspareunia or sexual enjoyment, although women who had midline episiotomies were more likely to resume intercourse within a shorter time after childbirth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The apex of a median episiotomy points directly towards the maternal anus, so if an extension occurs, the anal sphincter is at high risk of injury. The incidence of third and fourth degree obstetric laceration is higher with a median episiotomy compared to that with mediolateral episiotomy or no episiotomy (RR 2.4-4.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/18,34-40\">",
"     18,34-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link&amp;anchor=H8#H8\">",
"     \"Fecal incontinence in adults\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mediolateral",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mediolateral episiotomy is more commonly employed in Europe and the Commonwealth countries. The incision is initiated at the fourchette and cut at an angle (usually to the maternal right for right handed clinicians) that may be almost perpendicular to the midline (80 to 90 degrees); however, after delivery of the infant, this angle becomes smaller, approaching 45 degrees, since the perineum is no longer stretched and distorted by the fetal presenting part. The final angle of the scar should be at 30 to 60 degrees from the midline to minimize the occurrence of sphincter injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/32,41\">",
"     32,41",
"    </a>",
"    ]. The incision should be 3 to 5 cm in length.",
"   </p>",
"   <p>",
"    The anatomical structures incised include the vaginal epithelium, transverse perineal and bulbocavernosus muscles, and perineal skin. If the incision is large, adipose tissue within ischiorectal fossa may be exposed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advantages and disadvantages &mdash; The major advantage of the mediolateral episiotomy is that the surgical incision is directed away from the maternal anal sphincter, thereby partially protecting the sphincter and the rectum from injury due to extension [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/33,34,42,43\">",
"       33,34,42,43",
"      </a>",
"      ]. The only prospective, randomized, controlled trial evaluating this issue found that the incidence of",
"      <span class=\"nowrap\">",
"       third/fourth",
"      </span>",
"      degree lacerations with median and mediolateral episiotomy was 11 and 2 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Retrospective studies have reported mediolateral episiotomy was associated with a two- to six-fold reduction in these injuries compared to no episiotomy or a midline episiotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/34,43-45\">",
"       34,43-45",
"      </a>",
"      ], and one sphincter injury would be prevented for every five forceps (or 12 vacuum) deliveries performed with mediolateral episiotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/46\">",
"       46",
"      </a>",
"      ]. However, routine use of mediolateral episiotomy did not result in significant reduction of anal sphincter tears compared to no episiotomy, only selective use appeared to be effective [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/34\">",
"       34",
"      </a>",
"      ]. Randomized trials are needed to clarify optimal use of this procedure.",
"      <br/>",
"      <br/>",
"      The mediolateral episiotomy incises a greater volume of muscle with a rich vascular supply than the median procedure, thus it is associated with more blood loss [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. The repair is also more technically challenging. Some reports suggested mediolateral episiotomy was associated with more postpartum pain and dyspareunia than either midline or no episiotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/19\">",
"       19",
"      </a>",
"      ], but this has not been confirmed in randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     J incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique is favored by some practitioners, but is not widely used. The purpose of the \"J\" incision is to combine the advantages of the median and mediolateral techniques, while avoiding their disadvantages. The incision starts at the fourchette, is initially extended caudally in the midline and then curved laterally at an angle, similar to the letter \"J\". The anatomical structures incised include the vaginal epithelium, perineal body, and the junction of the perineal body with the bulbocavernosus muscle and perineal skin. Ideally, the transverse perineal muscle is spared because the lateral part of the incision should be below this muscle; however, it is difficult to ensure that it is not incised.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advantages and disadvantages &mdash; This hybrid of a median and mediolateral episiotomy may optimize the advantages and minimize the disadvantages of the composite techniques. The apex of the incision points away from the rectum to guide any further extension away from this structure. Postpartum pain and dyspareunia are probably similar to that with the mediolateral technique, while ease of repair lies between the median and mediolateral procedures. Unfortunately, there are no reliable scientific data on which to base conclusions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are various modifications of the above techniques that may be preferred by individual practitioners. These procedures are usually modifications of the median episiotomy, such as the addition of bilateral transverse cuts to the apex to create an inverted \"T\" [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/49\">",
"     49",
"    </a>",
"    ]. This procedure increases the area of the vaginal opening more than a single cut (",
"    <a class=\"graphic graphic_figure graphicRef78159 \" href=\"UTD.htm?15/50/16160\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lateral episiotomy is begun at 1 to 2 cm lateral to midline, and the incision is directed laterally toward the ischial tuberosity. It is rarely used.",
"   </p>",
"   <p>",
"    An anterior episiotomy is known as deinfibulation (or defibulation). It is only indicated in the setting of previous female circumcision (ie, female genital mutilation). The fused labia minora are incised in the midline toward the pubis to reveal the external urethral meatus; the clitoral remnants should not be incised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34133?source=see_link\">",
"     \"Female genital cutting (circumcision)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair of episiotomy and perineal lacerations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3433?source=see_link\">",
"     \"Repair of episiotomy and perineal lacerations associated with childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of episiotomy are bleeding, infection, dehiscence, and extension (",
"    <a class=\"graphic graphic_table graphicRef77532 \" href=\"UTD.htm?6/38/6763\">",
"     table 1",
"    </a>",
"    ). Bleeding can usually be controlled with pressure or sutures, although a hematoma may occasionally develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16455?source=see_link\">",
"     \"Management of hematomas incurred as a result of obstetrical delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of episiotomy infection include fever, wound tenderness, and purulent discharge, typically occurring six to eight days following delivery. Most infections will resolve with local perineal care. Opening the incision to drain an abscess may be necessary (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link&amp;anchor=H8#H8\">",
"     \"Skin abscesses, furuncles, and carbuncles\", section on 'Treatment'",
"    </a>",
"    ). The area can be allowed to heal spontaneously if the defect is small; large defects are repaired surgically (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Dehiscence'",
"    </a>",
"    below). In rare cases, necrotizing fasciitis or a fistula may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31464?source=see_link\">",
"     \"Vulvar abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of these problems can occur from childbirth alone, in the absence of episiotomy, so it is difficult to determine whether there is excess risk due to this procedure without appropriately controlled studies. A large randomized trial of selective versus liberal use of episiotomy demonstrated that the former policy resulted in fewer healing complications and fewer patients reporting perineal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/5\">",
"     5",
"    </a>",
"    ]. However, reduced use of episiotomy was associated with higher rates of perineal trauma, especially anteriorly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/3,5,20\">",
"     3,5,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Extension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extension of the episiotomy to create a third or fourth degree laceration or deep vaginal tear is one of the more common complications of episiotomy. The prevalence of third or fourth degree lacerations by type of episiotomy among women delivering their first vaginal birth has been reported to be: no episiotomy (1 percent), mediolateral episiotomy (9 percent), and median episiotomy (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for severe lacerations include late timing, inadequate length of the incision, macrosomia, previous third or fourth degree laceration (in multiparous women), midline episiotomy, instrumental vaginal delivery, Asian ethnicity, occiput posterior position, and nulliparity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. One group used a classification and regression tree to analyze data from over 25,000 term vaginal births and estimated the risk of a",
"    <span class=\"nowrap\">",
"     third/fourth",
"    </span>",
"    degree laceration was almost 70 percent in the setting of forceps delivery performed with an episiotomy for an infant with birthweight over 3600 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/57\">",
"     57",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dehiscence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dehiscence is a particularly onerous complication of episiotomy. It is reported to occur after 0.1 to 2 percent of procedures, but data regarding a preceding third versus fourth degree laceration are scanty [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/58\">",
"     58",
"    </a>",
"    ]. One case-cohort series of 390 women who underwent repair of a fourth degree perineal tear found approximately 5 percent had postpartum perineal complications: dehiscence only (1.8 percent), infection and dehiscence (2.8 percent), infection only (0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although closure of these defects was routinely delayed for two or more months after delivery, early repair (within two weeks of delivery) has become common and appears successful [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Prior to surgical repair, one group recommends debriding the area of all necrotic tissue and sutures, irrigating daily, and administering intravenous antibiotics if there is evidence of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13992/abstract/58\">",
"     58",
"    </a>",
"    ]. A mechanical bowel preparation using an oral solution is given the night before surgery.",
"   </p>",
"   <p>",
"    When the wound is free of exudate and is granulating, it is closed in a manner similar to that with a primary repair. Postoperatively, a low residue diet is prescribed initially and advanced to a regular diet. Nothing is placed in the rectum or vagina until the wound is healed. Sitz baths, heat lamp to the perineum, and mild analgesics help to relieve patient discomfort. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3433?source=see_link\">",
"     \"Repair of episiotomy and perineal lacerations associated with childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/0/22529?source=see_link\">",
"       \"Patient information: Maternal injuries from childbirth (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An episiotomy is performed to enlarge the pelvic soft tissue outlet and thereby prevent severe spontaneous perineal lacerations, facilitate delivery, and shorten the time to fetal expulsion. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Rationale for episiotomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend avoiding routine episiotomy (median or mediolateral), given there is no proven benefit to this practice (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest use of episiotomy be limited to deliveries with a high risk of severe perineal laceration, significant soft tissue dystocia, or need to facilitate delivery of a possibly compromised fetus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Routine versus restricted use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is inadequate evidence that episiotomy results in more postpartum pain than not performing an episiotomy. The possibility of sexual dysfunction appears to be greater when an episiotomy is performed than when it is not; however, this effect is of a short duration. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Episiotomy reduces the rate of anterior perineal trauma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Median episiotomy is associated with less blood loss and is easier to perform and repair than the mediolateral procedure. However, median episiotomy is also associated with a higher risk of injury to the maternal anal sphincter and rectum than mediolateral episiotomies or spontaneous obstetrical lacerations. When episiotomy is indicated, we suggest a mediolateral rather than median approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Median'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Mediolateral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/1\">",
"      Weber AM, Meyn L. Episiotomy use in the United States, 1979-1997. Obstet Gynecol 2002; 100:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/2\">",
"      Frankman EA, Wang L, Bunker CH, Lowder JL. Episiotomy in the United States: has anything changed? Am J Obstet Gynecol 2009; 200:573.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/3\">",
"      Carroli G, Belizan J. Episiotomy for vaginal birth. Cochrane Database Syst Rev 2000; :CD000081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/4\">",
"      R&ouml;ckner G, Fianu-Jonasson A. Changed pattern in the use of episiotomy in Sweden. Br J Obstet Gynaecol 1999; 106:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/5\">",
"      Routine vs selective episiotomy: a randomised controlled trial. Argentine Episiotomy Trial Collaborative Group. Lancet 1993; 342:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/6\">",
"      Robinson JN, Norwitz ER, Cohen AP, Lieberman E. Predictors of episiotomy use at first spontaneous vaginal delivery. Obstet Gynecol 2000; 96:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/7\">",
"      Gerrits DD, Brand R, Gravenhorst JB. The use of an episiotomy in relation to the professional education of the delivery attendant. Eur J Obstet Gynecol Reprod Biol 1994; 56:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/8\">",
"      Howden NL, Weber AM, Meyn LA. Episiotomy use among residents and faculty compared with private practitioners. Obstet Gynecol 2004; 103:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/9\">",
"      Gupta JK, Hofmeyr GJ, Shehmar M. Position in the second stage of labour for women without epidural anaesthesia. Cochrane Database Syst Rev 2012; 5:CD002006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/10\">",
"      Newman MG, Lindsay MK, Graves W. The effect of epidural analgesia on rates of episiotomy use and episiotomy extension in an inner-city hospital. J Matern Fetal Med 2001; 10:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/11\">",
"      Hueston WJ. Factors associated with the use of episiotomy during vaginal delivery. Obstet Gynecol 1996; 87:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/12\">",
"      American College of Obstetricians-Gynecologists. ACOG Practice Bulletin. Episiotomy. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 71, April 2006. Obstet Gynecol 2006; 107:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/13\">",
"      R&auml;is&auml;nen S, Vehvil&auml;inen-Julkunen K, Gissler M, Heinonen S. Hospital-based lateral episiotomy and obstetric anal sphincter injury rates: a retrospective population-based register study. Am J Obstet Gynecol 2012; 206:347.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/14\">",
"      Bottoms S. Delivery of the premature infant. Clin Obstet Gynecol 1995; 38:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/15\">",
"      Eason E, Labrecque M, Wells G, Feldman P. Preventing perineal trauma during childbirth: a systematic review. Obstet Gynecol 2000; 95:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/16\">",
"      Macarthur AJ, Macarthur C. Incidence, severity, and determinants of perineal pain after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol 2004; 191:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/17\">",
"      Signorello LB, Harlow BL, Chekos AK, Repke JT. Postpartum sexual functioning and its relationship to perineal trauma: a retrospective cohort study of primiparous women. Am J Obstet Gynecol 2001; 184:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/18\">",
"      Klein MC, Gauthier RJ, Robbins JM, et al. Relationship of episiotomy to perineal trauma and morbidity, sexual dysfunction, and pelvic floor relaxation. Am J Obstet Gynecol 1994; 171:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/19\">",
"      Sartore A, De Seta F, Maso G, et al. The effects of mediolateral episiotomy on pelvic floor function after vaginal delivery. Obstet Gynecol 2004; 103:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/20\">",
"      Sleep J, Grant A, Garcia J, et al. West Berkshire perineal management trial. Br Med J (Clin Res Ed) 1984; 289:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/21\">",
"      Thranov I, Kringelbach AM, Melchior E, et al. Postpartum symptoms. Episiotomy or tear at vaginal delivery. Acta Obstet Gynecol Scand 1990; 69:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/22\">",
"      Sleep J, Grant A. West Berkshire perineal management trial: three year follow up. Br Med J (Clin Res Ed) 1987; 295:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/23\">",
"      Fleming N, Newton ER, Roberts J. Changes in postpartum perineal muscle function in women with and without episiotomies. J Midwifery Womens Health 2003; 48:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/24\">",
"      R&ouml;ckner G, Jonasson A, Olund A. The effect of mediolateral episiotomy at delivery on pelvic floor muscle strength evaluated with vaginal cones. Acta Obstet Gynecol Scand 1991; 70:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/25\">",
"      Handa VL, Blomquist JL, McDermott KC, et al. Pelvic floor disorders after vaginal birth: effect of episiotomy, perineal laceration, and operative birth. Obstet Gynecol 2012; 119:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/26\">",
"      Hartmann K, Viswanathan M, Palmieri R, et al. Outcomes of routine episiotomy: a systematic review. JAMA 2005; 293:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/27\">",
"      Fritel X, Schaal JP, Fauconnier A, et al. Pelvic floor disorders 4 years after first delivery: a comparative study of restrictive versus systematic episiotomy. BJOG 2008; 115:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/28\">",
"      Borghi J, Fox-Rushby J, Bergel E, et al. The cost-effectiveness of routine versus restrictive episiotomy in Argentina. Am J Obstet Gynecol 2002; 186:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/29\">",
"      Faruel-Fosse H, Vendittelli F. [Can we reduce the episotomy rate?]. J Gynecol Obstet Biol Reprod (Paris) 2006; 35:1S68.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists. The management of third- and fourth-degree perineal tears. Green-top guideline No. 29, March 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/31\">",
"      Kalis V, Laine K, de Leeuw JW, et al. Classification of episiotomy: towards a standardisation of terminology. BJOG 2012; 119:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/32\">",
"      Stedenfeldt M, Pirhonen J, Blix E, et al. Episiotomy characteristics and risks for obstetric anal sphincter injuries: a case-control study. BJOG 2012; 119:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/33\">",
"      Coats PM, Chan KK, Wilkins M, Beard RJ. A comparison between midline and mediolateral episiotomies. Br J Obstet Gynaecol 1980; 87:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/34\">",
"      Shiono P, Klebanoff MA, Carey JC. Midline episiotomies: more harm than good? Obstet Gynecol 1990; 75:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/35\">",
"      Labrecque M, Baillargeon L, Dallaire M, et al. Association between median episiotomy and severe perineal lacerations in primiparous women. CMAJ 1997; 156:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/36\">",
"      Helwig JT, Thorp JM Jr, Bowes WA Jr. Does midline episiotomy increase the risk of third- and fourth-degree lacerations in operative vaginal deliveries? Obstet Gynecol 1993; 82:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/37\">",
"      Robinson JN, Norwitz ER, Cohen AP, et al. Episiotomy, operative vaginal delivery, and significant perinatal trauma in nulliparous women. Am J Obstet Gynecol 1999; 181:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/38\">",
"      KALTREIDER DF, DIXON DM. A study of 710 complete lacerations following central episiotomy. South Med J 1948; 41:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/39\">",
"      Harris RE. An evaluation of the median episiotomy. Am J Obstet Gynecol 1970; 106:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/40\">",
"      Beynon CL. Midline episiotomy as a routine procedure. J Obstet Gynaecol Br Commonw 1974; 81:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/41\">",
"      Eogan M, Daly L, O'Connell PR, O'Herlihy C. Does the angle of episiotomy affect the incidence of anal sphincter injury? BJOG 2006; 113:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/42\">",
"      Legino LJ, Woods MP, Rayburn WF, McGoogan LS. Third- and fourth-degree perineal tears. 50 year's experience at a university hospital. J Reprod Med 1988; 33:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/43\">",
"      Poen AC, Felt-Bersma RJ, Dekker GA, et al. Third degree obstetric perineal tears: risk factors and the preventive role of mediolateral episiotomy. Br J Obstet Gynaecol 1997; 104:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/44\">",
"      Anthony S, Buitendijk SE, Zondervan KT, et al. Episiotomies and the occurrence of severe perineal lacerations. Br J Obstet Gynaecol 1994; 101:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/45\">",
"      de Vogel J, van der Leeuw-van Beek A, Gietelink D, et al. The effect of a mediolateral episiotomy during operative vaginal delivery on the risk of developing obstetrical anal sphincter injuries. Am J Obstet Gynecol 2012; 206:404.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/46\">",
"      de Leeuw JW, de Wit C, Kuijken JP, Bruinse HW. Mediolateral episiotomy reduces the risk for anal sphincter injury during operative vaginal delivery. BJOG 2008; 115:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/47\">",
"      Stones RW, Paterson CM, Saunders NJ. Risk factors for major obstetric haemorrhage. Eur J Obstet Gynecol Reprod Biol 1993; 48:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/48\">",
"      Combs CA, Murphy EL, Laros RK Jr. Factors associated with postpartum hemorrhage with vaginal birth. Obstet Gynecol 1991; 77:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/49\">",
"      May JL. Modified median episiotomy minimizes the risk of third-degree tears. Obstet Gynecol 1994; 83:156.",
"     </a>",
"    </li>",
"    <li>",
"     Owen, J, Hauth, JC. Episiotomy infection and dehiscence. In: Gilstrap, LC III, Faro, S (eds) Infections in Pregnancy, Alan R Liss, New York 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/51\">",
"      Hudelist G, Gelle'n J, Singer C, et al. Factors predicting severe perineal trauma during childbirth: role of forceps delivery routinely combined with mediolateral episiotomy. Am J Obstet Gynecol 2005; 192:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/52\">",
"      Jones KD. Incidence and risk factors for third degree perineal tears. Int J Gynaecol Obstet 2000; 71:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/53\">",
"      Angioli R, G&oacute;mez-Mar&iacute;n O, Cantuaria G, O'sullivan MJ. Severe perineal lacerations during vaginal delivery: the University of Miami experience. Am J Obstet Gynecol 2000; 182:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/54\">",
"      Nager CW, Helliwell JP. Episiotomy increases perineal laceration length in primiparous women. Am J Obstet Gynecol 2001; 185:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/55\">",
"      de Leeuw JW, Struijk PC, Vierhout ME, Wallenburg HC. Risk factors for third degree perineal ruptures during delivery. BJOG 2001; 108:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/56\">",
"      Bodner-Adler B, Bodner K, Kaider A, et al. Risk factors for third-degree perineal tears in vaginal delivery, with an analysis of episiotomy types. J Reprod Med 2001; 46:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/57\">",
"      Hamilton EF, Smith S, Yang L, et al. Third- and fourth-degree perineal lacerations: defining high-risk clinical clusters. Am J Obstet Gynecol 2011; 204:309.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/58\">",
"      Ramin SM, Gilstrap LC 3rd. Episiotomy and early repair of dehiscence. Clin Obstet Gynecol 1994; 37:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/59\">",
"      Goldaber KG, Wendel PJ, McIntire DD, Wendel GD Jr. Postpartum perineal morbidity after fourth-degree perineal repair. Am J Obstet Gynecol 1993; 168:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/60\">",
"      Ramin SM, Ramus RM, Little BB, Gilstrap LC 3rd. Early repair of episiotomy dehiscence associated with infection. Am J Obstet Gynecol 1992; 167:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/61\">",
"      Hankins GD, Hauth JC, Gilstrap LC 3rd, et al. Early repair of episiotomy dehiscence. Obstet Gynecol 1990; 75:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13992/abstract/62\">",
"      Arona AJ, al-Marayati L, Grimes DA, Ballard CA. Early secondary repair of third- and fourth-degree perineal lacerations after outpatient wound preparation. Obstet Gynecol 1995; 86:294.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4478 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13992=[""].join("\n");
var outline_f13_42_13992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF EPISIOTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RATIONALE FOR EPISIOTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Episiotomy versus no episiotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Routine versus restricted use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Median",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mediolateral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - J incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dehiscence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4478\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4478|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29119\" title=\"figure 1\">",
"      Types of episiotomy incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/50/16160\" title=\"figure 2\">",
"      Inverted T episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4478|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/38/6763\" title=\"table 1\">",
"      Episiotomy complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34133?source=related_link\">",
"      Female genital cutting (circumcision)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16455?source=related_link\">",
"      Management of hematomas incurred as a result of obstetrical delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/0/22529?source=related_link\">",
"      Patient information: Maternal injuries from childbirth (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40439?source=related_link\">",
"      Pudendal and paracervical block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3433?source=related_link\">",
"      Repair of episiotomy and perineal lacerations associated with childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=related_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31464?source=related_link\">",
"      Vulvar abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_42_13993="Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment";
var content_f13_42_13993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13993/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13993/contributors\">",
"     Fabien Maldonado, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13993/contributors\">",
"     Andrew H Limper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13993/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13993/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13993/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13993/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13993/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/42/13993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse drug reactions (ADRs) due to antineoplastic agents are a common form of iatrogenic injury, and the lungs are a frequent target [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. While some antineoplastic agent-induced ADRs are potentially preventable (particularly those that are related to cumulative dosing), many are idiosyncratic and unpredictable.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the clinical presentation, pathogenesis, diagnosis, and treatment of pulmonary toxicity associated with antineoplastic agents. Specific patterns of lung injury seen with individual agents (",
"    <a class=\"graphic graphic_table graphicRef60543 \" href=\"UTD.htm?24/32/25100\">",
"     table 1",
"    </a>",
"    ) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17050?source=see_link\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=see_link\">",
"     \"Chlorambucil-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/46/33513?source=see_link\">",
"     \"Mitomycin-C pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=see_link\">",
"     \"Taxane-induced pulmonary toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some estimate that 10 to 20 percent of all patients treated with an antineoplastic agent have some form of lung toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The high prevalence may be a result of the lungs receiving the entire blood supply, leading to greater exposure to potentially harmful antineoplastic agents compared to other organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of antineoplastic agent-induced lung injury is poorly understood. Most toxic effects are thought to result from direct cytotoxicity. The following pathophysiologic mechanisms have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct injury to pneumocytes or the alveolar capillary endothelium with the subsequent release of cytokines and recruitment of inflammatory cells.",
"     </li>",
"     <li>",
"      The systemic release of cytokines (eg, by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ) may result in endothelial dysfunction, capillary leak syndrome, and noncardiogenic pulmonary edema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17050?source=see_link&amp;anchor=H12#H12\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\", section on 'Gemcitabine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cell-mediated lung injury due to activation of lymphocytes and alveolar macrophages. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H31#H31\">",
"       \"Drug allergy: Classification and clinical features\", section on 'Drug-induced hypersensitivity syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oxidative injury from free oxygen radicals (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -related lung injury). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"       \"Bleomycin-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidermal growth factor receptors (EGFR) are expressed on type II pneumocytes, and are involved in alveolar wall repair; agents targeting the EGFR may impair alveolar repair mechanisms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation recall pneumonitis is mediated by the presence of subclinical cumulative parenchymal radiation-induced injury that becomes apparent when another pulmonary insult (ie, cytotoxic chemotherapy) is encountered at a later date. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"       \"Radiation-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also conceivable that exposure to high fractions of inspired oxygen, common in cancer patients, could explain some of the predilection for lung toxicity; this has been best documented for patients exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of antineoplastic agent-induced lung disease is variable, and several clinical syndromes have been described (",
"    <a class=\"graphic graphic_table graphicRef60543 \" href=\"UTD.htm?24/32/25100\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/5\">",
"     5",
"    </a>",
"    ]. The exact definition of these clinical syndromes is unclear as different criteria and terminologies are frequently used. Most clinical trials do not report the details of pulmonary toxicity, and literature reports may describe pulmonary toxicity based upon clinical or radiographic criteria (eg, acute lung injury, pneumonitis, noncardiogenic pulmonary edema, acute respiratory distress syndrome (ARDS)) or on pathologic findings (eg, diffuse alveolar damage, organizing pneumonia, neutrophilic alveolitis) (",
"    <a class=\"graphic graphic_table graphicRef60543 \" href=\"UTD.htm?24/32/25100\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of most of these syndromes are nonspecific and include cough, dyspnea, low-grade fever, and hypoxemia. Chills and sputum production are rarely reported, while constitutional symptoms, such as weight loss, may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/6\">",
"     6",
"    </a>",
"    ]. Lung auscultation may reveal bibasilar crackles, but is often normal. Wheezing is rare, but when present, suggests a hypersensitivity mechanism with a component of bronchoconstriction. A concomitant morbilliform rash would provide evidence of hypersensitivity to a drug, such as drug-induced hypersensitivity (DIHS), also known as drug rash with eosinophilia and systemic symptoms (DRESS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link&amp;anchor=H18#H18\">",
"     \"Drug allergy: Pathogenesis\", section on 'IVb'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The timing of the clinical manifestations is variable; they may present early during the first cycle of therapy or with subsequent treatment courses. Except for rare cases of delayed fibrosis seen with nitrosoureas and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/8\">",
"     8",
"    </a>",
"    ], lung toxicity typically occurs within weeks to a few months after initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As most modern antineoplastic therapy protocols consist of multiple drugs, it may be difficult to pinpoint the specific agent that is responsible for the lung toxicity. Respiratory manifestations are almost never specific enough to incriminate one agent over another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing (PFT) often reveals a decrease in diffusing capacity for carbon monoxide (DLCO), which may be the first and the only PFT abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. A restrictive PFT pattern (ie, reduced total lung capacity (TLC) and reduced forced vital capacity (FVC)) may be present in advanced cases, or on long-term follow-up following acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal gas transfer may also be manifest in reduced oxygen saturation at rest or on exertion.",
"   </p>",
"   <p>",
"    Chemotherapy regimens that include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , platinum,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    are associated with significant reductions in DLCO; however, small changes do not correlate with symptoms or operability [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/9,15,16\">",
"     9,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various radiographic patterns of drug-induced injury are described, including patchy, unilateral or bilateral reticular markings, ground glass opacities or consolidations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/5,17,18\">",
"     5,17,18",
"    </a>",
"    ]. These patterns may be mixed in an individual patient. Pleural effusions and focal nodular consolidations that mimic tumor involvement may also be seen.",
"   </p>",
"   <p>",
"    The most common abnormalities on high resolution computed tomography (HRCT) are ground glass opacities, consolidation, interlobular septal thickening, and centrilobular nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/18\">",
"     18",
"    </a>",
"    ]. The pattern, distribution, and extent of HRCT abnormalities are of limited diagnostic and prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link&amp;anchor=H4#H4\">",
"     \"High resolution computed tomography of the lungs\", section on 'HRCT patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The radiographic manifestations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury are variable (",
"    <a class=\"graphic graphic_table graphicRef75991 \" href=\"UTD.htm?0/25/411\">",
"     table 2",
"    </a>",
"    ). The classic pattern of early pulmonary fibrosis includes bibasilar subpleural reticular and ground glass opacification with volume loss and blunting of the costophrenic angles; fine nodular densities may also be present. These early findings give way to progressive consolidation and honeycombing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation recall pneumonitis has been described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/5,19-24\">",
"     5,19-24",
"    </a>",
"    ]. Chest imaging shows a unique pattern of pulmonary opacities in exactly the same distribution as the previous radiation therapy portal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hilar lymphadenopathy is uncommon, except in the case of methotrexate-induced lung disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link&amp;anchor=H12#H12\">",
"     \"Methotrexate-induced lung injury\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bronchoscopy and bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific findings for drug-induced lung toxicity on bronchoscopy or bronchoalveolar lavage (BAL). BAL fluid cell counts are usually elevated; lymphocytosis, neutrophilia, or rarely, eosinophilia may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/5\">",
"     5",
"    </a>",
"    ]. Neither the pattern of cellularity, nor any other finding can specifically establish the diagnosis of drug-induced lung toxicity; the main role of bronchoscopy is to exclude infection or recurrent malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all histopathologic patterns of lung injury have been described in patients with pulmonary toxicity associated with antineoplastic agents, including usual interstitial pneumonia, nonspecific interstitial pneumonia, desquamative interstitial pneumonia, eosinophilic pneumonia, hypersensitivity pneumonia, organizing pneumonia, diffuse alveolar damage, alveolar hemorrhage, and rarely, non-necrotizing granulomatosis, pulmonary veno-occlusive disease, and alveolar proteinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=see_link\">",
"     \"Pulmonary veno-occlusive disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific tests establish the diagnosis of antineoplastic agent-induced pulmonary toxicity, other than rechallenge with the implicated agent after a period of discontinuation. Instead, the diagnosis is usually made on the basis the combination of the presence of a compatible clinical pattern (",
"    <a class=\"graphic graphic_table graphicRef60543 \" href=\"UTD.htm?24/32/25100\">",
"     table 1",
"    </a>",
"    ), a drug that is a known or suspected culprit, and the exclusion of infection or pulmonary involvement from the underlying malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Routine testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing (eg, complete cell counts, coagulation tests, B-type natriuretic peptide (BNP), blood cultures, sputum cultures, viral serology) is used to determine whether other disease processes are contributing to the patient's respiratory compromise.",
"   </p>",
"   <p>",
"    Pulmonary function tests are more important in assessing the degree of pulmonary impairment than in making a specific diagnosis. Radiographic studies are rarely specific enough to establish the diagnosis, but are helpful as a measure of disease severity and to exclude other processes (eg, pulmonary embolism). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main role of bronchoscopy and bronchoalveolar lavage (BAL) is to exclude other processes such as infection, diffuse alveolar hemorrhage, and lymphangitic spread of tumor.",
"   </p>",
"   <p>",
"    Lavage samples should be obtained and processed for bacterial, fungal, and mycobacterial smear, special stains, and culture. Samples can also be sent for viral culture and cytologic examination for viral inclusion bodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The BAL technique for identifying pulmonary hemorrhage includes three sequential lavages in a single site. The effluent typically shows increasingly hemorrhagic fluid with each successive sample. This is confirmed by cytologic studies showing hemosiderin-laden macrophages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link&amp;anchor=H12#H12\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cytologic analysis for malignant cells should also be performed. Bronchoalveolar cell dysplasia in acute lung injury and acute respiratory distress syndrome (ARDS) may mimic malignancy, so morphologic studies should be interpreted with caution and when possible combined with immunohistochemical or molecular testing to confirm the cell lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients without specific contraindications, transbronchial lung biopsy may improve the likelihood of identifying lymphangitic spread of tumor or an invasive fungal infection over BAL alone. In addition, biopsy allows distinction between colonization and invasion in fungal (or viral) infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link&amp;anchor=H3441165#H3441165\">",
"     \"Flexible bronchoscopy: Indications and contraindications\", section on 'Contraindications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main role for lung biopsy in the evaluation of patients with suspected lung injury from antineoplastic agents is to characterize the histopathologic pattern (eg, organizing pneumonia and nonspecific interstitial pneumonia) and to exclude other processes. Lung biopsy rarely establishes an antineoplastic agent as the definitive source of the lung injury, as there are no pathognomonic findings, and histologic criteria for drug-induced lung disease have not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of antineoplastic agent-induced lung toxicity is challenging and largely one of exclusion. For most patients with respiratory symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary infiltrates who might have antineoplastic agent-induced pulmonary toxicity, the differential diagnosis is extensive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection is a common cause of pulmonary infiltrates and respiratory compromise in patients with cancer. Patients undergoing chemotherapy are often immunosuppressed, both from the treatment and the underlying disease, and are prone to a variety of opportunistic pulmonary infections and atypical presentations of more common pneumonias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"       \"Pulmonary infections in immunocompromised patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"       \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation-induced lung injury may have a synergic effect on antineoplastic agent-induced lung toxicity in patients receiving concurrent or sequential chemotherapy plus radiation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"       \"Radiation-induced lung injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=see_link&amp;anchor=H7#H7\">",
"       \"Taxane-induced pulmonary toxicity\", section on 'Concomitant radiotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiogenic and non-cardiogenic pulmonary edema are occasionally encountered in patients treated with antineoplastic agents. As examples,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      is associated with a dose-dependent cardiomyopathy that may present as heart failure; cumulative exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      is associated with a capillary leak syndrome resulting in a clinical picture of noncardiogenic pulmonary edema with or without pleural effusions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=see_link&amp;anchor=H11#H11\">",
"       \"Taxane-induced pulmonary toxicity\", section on 'Capillary leakage and docetaxel'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pulmonary edema may also be unrelated to the antineoplastic therapy. In assessing the etiology of pulmonary edema, a cardiogenic cause is suggested if the echocardiogram suggests left ventricular dysfunction, and serum B-type natriuretic peptide (BNP) is elevated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"       \"Evaluation of acute decompensated heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct involvement of the lungs by the neoplastic process may occur (eg, pulmonary metastases, lymphangitic carcinomatosis, or pulmonary tumor embolism). This may be diagnosed by a typical radiographic pattern (eg, lymphangitic carcinomatosis), cytologic evidence of malignant cells, or lung biopsy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69355 graphicRef79160 \" href=\"UTD.htm?10/37/10839\">",
"       image 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23270?source=see_link\">",
"       \"Pulmonary tumor embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link&amp;anchor=H24#H24\">",
"       \"High resolution computed tomography of the lungs\", section on 'Lymphangitic carcinomatosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary hemorrhage, which may be unrelated to drug therapy or drug-related. Alveolar hemorrhage has been reported in patients with advanced squamous cell lung cancer who are treated with the anti-VEGF (vascular endothelial growth factor) monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      , a small molecule inhibitor of the VEGF tyrosine kinase [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/27\">",
"       27",
"      </a>",
"      ], as well as in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17050?source=see_link&amp;anchor=H12#H12\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\", section on 'Gemcitabine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these potential etiologies may have a clinical and radiographic appearance similar to antineoplastic agent-induced lung toxicity. They need to be carefully considered and excluded before one can make a presumptive diagnosis of drug toxicity.",
"   </p>",
"   <p>",
"    Establishing the diagnosis of drug toxicity is important, as it may have significant implications for clinical care. Depending on the clinical scenario, discontinuation of an agent on suspicion alone may deprive the patient of a potentially life-prolonging treatment (eg, a patient who develops pulmonary infiltrates while receiving adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for HER2-positive early breast cancer). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Trastuzumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, treatment of antineoplastic agent-induced pulmonary injury is empiric rather than evidence based. The key components include drug discontinuation, glucocorticoid therapy, and supportive care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drug discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the majority of antineoplastic agents, no specific treatment has proven effective besides discontinuation of the suspected offending agent. In general, suspicion of significant lung toxicity justifies discontinuation of the drug. However, the clinician involved in the decision-making process must carefully weigh risks and benefits, as well as the availability of alternative treatments, as drug discontinuation may result in elimination of a highly effective agent.",
"   </p>",
"   <p>",
"    An exception to this rule is the differentiation syndrome seen in patients with acute promyelocytic leukemia who are treated with a differentiating agent (ie, all-trans retinoic acid or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    ). In the differentiation syndrome, the differentiating agent can usually be continued, as long as glucocorticoid therapy is initiated promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the development of severe respiratory compromise may force discontinuation of the differentiating agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link&amp;anchor=H20#H20\">",
"     \"Differentiation (retinoic acid) syndrome\", section on 'Differentiation agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate glucocorticoid therapy usually depends on the severity and rapidity of worsening of pulmonary impairment. The evidence to support benefit of glucocorticoids in the setting of drug-induced lung toxicity is largely observational [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/25\">",
"     25",
"    </a>",
"    ]. Additional support comes from the observation that a histopathologic pattern consistent with glucocorticoid responsiveness (eg, nonspecific interstitial pneumonia, organizing pneumonia, eosinophilic pneumonia) is often observed in patients with acute or subacute onset of pulmonary toxicity who undergo lung biopsy. However, clinicians are often faced with choosing whether to initiate systemic glucocorticoids before a histopathologic diagnosis is available.",
"   </p>",
"   <p>",
"    For patients who have stable or improving pneumonitis, with the exception of the differentiation syndrome described above, glucocorticoids are generally withheld while observing for spontaneous improvement, as resolution of pulmonary toxicity often accompanies drug discontinuation.",
"   </p>",
"   <p>",
"    In contrast, empiric glucocorticoid therapy is usually initiated in a patient who has rapidly progressive or more severe pulmonary toxicity, although evidence from randomized trials to support this practice is lacking. Severe lung toxicity is characterized by dyspnea at rest, a decrease in oxygen saturation below 90 percent or more than a 4 percent decrease from baseline, worsening clinical status, or the need for ventilatory support. According to the National Cancer Institute common toxicity criteria (NCI-CTC) used to grade the severity of",
"    <span class=\"nowrap\">",
"     pneumonitis/pulmonary",
"    </span>",
"    infiltrates, this severity constitutes grade 3 or 4 toxicity (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"UTD.htm?18/50/19243\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Possible exceptions to the empiric use of glucocorticoids would include patients with a strong contraindication to glucocorticoids and those with evidence of a disease process that is unlikely to be glucocorticoid-responsive, such as veno-occlusive disease or advanced usual interstitial pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=see_link&amp;anchor=H10#H10\">",
"     \"Pulmonary veno-occlusive disease\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link\">",
"     \"Treatment of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When considering the option of systemic glucocorticoid therapy, it is mandatory to exclude an infectious etiology with appropriate stains and cultures, often including BAL. Empiric antimicrobial therapy directed at likely pathogens is often indicated while diagnostic procedures and cultures are performed. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Bronchoscopy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no established glucocorticoid treatment schedule, but severe respiratory compromise is often treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60 mg daily; intravenous glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    with doses up to 1 gm daily for three days) have been be used in patients who have impending respiratory failure or require mechanical ventilation. If the patient's response permits, tapering of the oral dose can be carried out over one to two months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care may include supplemental oxygen, inhaled bronchodilating medication (eg, beta agonists) when there is evidence of bronchoconstriction (eg, wheezing, airflow obstruction on pulmonary function tests), and mechanical ventilation, if clinically indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/5,29\">",
"     5,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Particularly in patients who have received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , supplemental oxygen using high inspired O2 concentrations should be avoided; supplemental oxygen should only be added when the oxygen saturation is below 89 percent and then titrated to an oxygen saturation of 89 to 93 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link&amp;anchor=H9#H9\">",
"     \"Bleomycin-induced lung injury\", section on 'High fraction of inspired oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to reintroduce the same drug in a patient who has recovered from drug-induced pulmonary toxicity must be made on a case by case basis, and should be based upon the individual agent, the severity of the reaction, and the availability of alternative therapies. When the diagnosis of symptomatic pulmonary toxicity from an antineoplastic agent is reasonably secure, we generally do not reintroduce the agent. However, there are some exceptions. For example, successful rechallenge has been reported with the differentiating agents (ie, all-trans retinoic acid or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , and possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link&amp;anchor=H20#H20\">",
"     \"Differentiation (retinoic acid) syndrome\", section on 'Differentiation agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Bcr-Abl tyrosine kinase inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H20#H20\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Rapamycin and analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening methods to detect early evidence of respiratory impairment include asking about dyspnea, auscultation for crackles, serial chest radiographs, and serial pulmonary function tests. However, the role of screening for early evidence of lung toxicity remains unclear, largely because of the lack of specificity of available tests.",
"   </p>",
"   <p>",
"    Many centers perform serial monitoring of DLCO in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , particularly when the cumulative dose approaches 400 units. Several authors recommend that bleomycin be discontinued if the DLCO falls to less than 60 percent of an individual's baseline value. The US Food and Drug Administration-approved package insert recommends frequent chest radiographs in patients receiving bleomycin, and optional monthly determinations of DLCO with discontinuation of drug when the DLCO falls to below 30 to 35 percent of the pretreatment value. However, many other institutions do not routinely monitor DLCO during bleomycin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link&amp;anchor=H18#H18\">",
"     \"Bleomycin-induced lung injury\", section on 'Screening for lung toxicity during therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring of uptake on 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning is being evaluated as another potential screening method. Increased uptake on PET scanning has been reported in patients with pneumonitis caused by several different antineoplastic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13993/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. However, a PET scan would not differentiate between lymphangitic tumor and drug-induced pneumonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antineoplastic agent-induced pulmonary toxicity is relatively frequent and the diagnosis should be entertained once careful investigation has excluded alternative explanations, including opportunistic infections, radiation-induced lung injury, or metastatic involvement of the lungs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various radiographic patterns of drug-induced injury are described, including alveolar, interstitial, or mixed opacities, pleural effusions, and focal nodular consolidations that mimic tumor involvement. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main purpose of bronchoalveolar lavage (BAL) is to exclude other processes such as infection, alveolar hemorrhage, and metastatic spread of the underlying cancer. A lung biopsy is indicated when the patient has progressive or severe disease and the cause of the pneumonitis is uncertain. Drug-induced lung disease can cause a broad spectrum of histologic patterns. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of chemotherapy-induced pneumonitis can be made with some confidence when pneumonitis develops shortly after the initiation of treatment, an alternative explanation for the respiratory compromise is lacking, and resolution of the pneumonitis follows withdrawal of the presumed agent. Establishing the diagnosis may have dramatic consequences for the patient, potentially leading to discontinuation of a highly effective agent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of lung toxicity caused by antineoplastic agents includes discontinuation of the drug, systemic glucocorticoids for more severe lung toxicity, and supportive care. No specific treatment has proven effective besides discontinuation of the suspected offending agent. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with pulmonary toxicity caused by an antineoplastic agent, we recommend discontinuation of the agent, rather than continuing it (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). An exception is the differentiation syndrome, in which the differentiating agent (ie, all-trans retinoic acid or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"       arsenic trioxide",
"      </a>",
"      ) can usually be continued unless respiratory failure is imminent. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Drug discontinuation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute or subacute onset of severe pulmonary toxicity (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or more than 4 percent decrease from baseline, or worsening clinical status), we recommend initiating systemic glucocorticoid therapy, rather than observation and supportive care alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We generally use oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60 mg daily; intravenous glucocorticoids may be used initially in patients who have impending respiratory failure. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with less severe and less rapidly progressive respiratory impairment and also those with a clinical presentation or pathology indicative of a pulmonary disease process that is unlikely to be glucocorticoid-responsive (eg, pulmonary veno-occlusive disease or usual interstitial pneumonitis), we suggest not using systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the clinical response permits, tapering of oral glucocorticoids can be carried out over one to two months. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/1\">",
"      Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001; 68:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/2\">",
"      Rosenow EC 3rd, Limper AH. Drug-induced pulmonary disease. Semin Respir Infect 1995; 10:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/3\">",
"      Snyder LS, Hertz MI. Cytotoxic drug-induced lung injury. Semin Respir Infect 1988; 3:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/4\">",
"      Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/5\">",
"      Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/6\">",
"      Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/7\">",
"      Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/8\">",
"      O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990; 323:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/9\">",
"      Yerushalmi R, Kramer MR, Rizel S, et al. Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Ann Oncol 2009; 20:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/10\">",
"      Wardley AM, Hiller L, Howard HC, et al. tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. Br J Cancer 2008; 99:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/11\">",
"      Dimopoulou I, Galani H, Dafni U, et al. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 2002; 94:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/12\">",
"      Leo F, Solli P, Spaggiari L, et al. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg 2004; 77:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/13\">",
"      Bossi G, Cerveri I, Volpini E, et al. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann Oncol 1997; 8 Suppl 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/14\">",
"      Castro M, Veeder MH, Mailliard JA, et al. A prospective study of pulmonary function in patients receiving mitomycin. Chest 1996; 109:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/15\">",
"      Dimopoulou I, Efstathiou E, Samakovli A, et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 2004; 15:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/16\">",
"      Rivera MP, Detterbeck FC, Socinski MA, et al. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. Chest 2009; 135:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/17\">",
"      Cleverley JR, Screaton NJ, Hiorns MP, et al. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/18\">",
"      Torrisi JM, Schwartz LH, Gollub MJ, et al. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011; 258:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/19\">",
"      Vegesna V, Withers HR, McBride WH, Holly FE. Adriamycin-induced recall of radiation pneumonitis and epilation in lung and hair follicles of mouse. Int J Radiat Oncol Biol Phys 1992; 23:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/20\">",
"      Kataoka M, Kawamura M, Nishiyama Y, et al. [A case with delayed-onset radiation pneumonitis suspected to be induced by oral etoposide]. Nihon Igaku Hoshasen Gakkai Zasshi 1992; 52:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/21\">",
"      Schweitzer VG, Juillard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995; 76:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/22\">",
"      Thomas PS, Agrawal S, Gore M, Geddes DM. Recall lung pneumonitis due to carmustine after radiotherapy. Thorax 1995; 50:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/23\">",
"      Miya T, Ono Y, Tanaka H, et al. [Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report]. Nihon Kokyuki Gakkai Zasshi 2003; 41:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/24\">",
"      Schwarte S, Wagner K, Karstens JH, Bremer M. Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol 2007; 183:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/25\">",
"      Camus P, Bonniaud P, Fanton A, et al. Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med 2004; 25:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/26\">",
"      Poletti V, Poletti G, Murer B, et al. Bronchoalveolar lavage in malignancy. Semin Respir Crit Care Med 2007; 28:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/27\">",
"      Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:4274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/28\">",
"      Nicolls MR, Terada LS, Tuder RM, et al. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998; 158:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/29\">",
"      Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/30\">",
"      Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica 2007; 92:e120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/31\">",
"      von Rohr L, Klaeser B, Joerger M, et al. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 2007; 30:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/32\">",
"      Post MC, Grutters JC, Verzijlbergen JF, Biesma DH. PET scintigraphy of etoposide-induced pulmonary toxicity. Clin Nucl Med 2007; 32:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/33\">",
"      Kalkanis D, Stefanovic A, Paes F, et al. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma 2009; 50:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13993/abstract/34\">",
"      Yamane T, Daimaru O, Ito S, et al. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma. Ann Nucl Med 2008; 22:719.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4315 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13993=[""].join("\n");
var outline_f13_42_13993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bronchoscopy and bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Routine testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drug discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4315|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/34/28192\" title=\"diagnostic image 1A\">",
"      Lymphangitic cancer CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/45/11987\" title=\"diagnostic image 1B\">",
"      Lymphangitic cancer CT II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/32/25100\" title=\"table 1\">",
"      Pulm tox neoplastic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/25/411\" title=\"table 2\">",
"      Bleomycin pneumonitis appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/50/19243\" title=\"table 3\">",
"      NCI CTCAE pneumonitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=related_link\">",
"      Busulfan-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=related_link\">",
"      Chlorambucil-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=related_link\">",
"      Differentiation (retinoic acid) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/46/33513?source=related_link\">",
"      Mitomycin-C pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=related_link\">",
"      Nitrosourea-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17050?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23270?source=related_link\">",
"      Pulmonary tumor embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=related_link\">",
"      Pulmonary veno-occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=related_link\">",
"      Taxane-induced pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_42_13994="Overview of nontuberculous mycobacterial lymphadenitis in children";
var content_f13_42_13994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of nontuberculous mycobacterial lymphadenitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13994/contributors\">",
"     Andrea T Cruz, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13994/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/42/13994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/42/13994/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/42/13994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2272512883\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacteria (NTM) are a miscellaneous collection of acid-fast bacteria that are widespread in the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1\">",
"     1",
"    </a>",
"    ]. They have been isolated from numerous environmental sources including water, soil, food products, and domestic and wild animals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"     2",
"    </a>",
"    ]. Nosocomial transmission has occurred with medical equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 130 species of have been identified, not all of which have been documented to cause disease in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. NTM pathogens are classified as rapidly growing or slowly growing (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ). Rapidly growing species grow within seven days and include",
"    <em>",
"     Mycobacterium fortuitum, M. abscessus,",
"    </em>",
"    and",
"    <em>",
"     M. chelonae",
"    </em>",
"    . Slowly growing species require several weeks to grow and include",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC),",
"    <em>",
"     M. marinum,",
"    </em>",
"    and",
"    <em>",
"     M. kansasii",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTM can cause a broad range of infections that vary depending on the particular NTM species and the host. In children, NTM cause four main clinical syndromes: lymphadenitis, skin and soft tissue infection (SSTI), pulmonary disease (predominantly in children with underlying pulmonary conditions), and disseminated disease (predominantly in children with immune compromise).",
"   </p>",
"   <p>",
"    This topic will provide an overview of NTM lymphadenitis in children. NTM SSTI, pulmonary infections, disseminated infections, and bacteremia in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7722?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial skin and soft tissue infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/282?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial pulmonary infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=see_link\">",
"     \"Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512896\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case series of nontuberculous mycobacterial lymphadenitis among children in the United States, the majority of cases are caused by",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC), which includes",
"    <em>",
"     M. avium",
"    </em>",
"    and",
"    <em>",
"     M. intracellulare",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. In series from other countries, MAC and",
"    <em>",
"     M. haemophilum",
"    </em>",
"    are frequently isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512904\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the true burden of nontuberculous mycobacterial (NTM) infections in children are unavailable; in part because NTM infections may be asymptomatic and because NTM infections are not communicable, reporting of NTM infections is not required in the United States or many other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"     2",
"    </a>",
"    ]. Nonetheless, the overall prevalence of NTM disease appears to be increasing (possibly as a result of enhanced detection) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,16-19\">",
"     10,16-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In population-based surveillance studies, estimates of the annual incidence of NTM in children range widely: from 0.8 per 100,000 children per in Australia, to 3.1 per 100,000 children in Germany, to 77 per 100,000 children in the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In each of these studies, lymphadenitis was the most common presentation.",
"   </p>",
"   <p>",
"    NTM are transmitted through environmental sources.",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC), the most common cause of lymphadenitis, is found in soil and water (from both natural and treated water) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. Aquatic transmission of NTM is facilitated by the formation of biofilms, which permit survival under a variety of environmental conditions and allow dissemination of large numbers of organisms when they become detached [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of NTM lymphadenitis occur in immunocompetent children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,10,21\">",
"     1,10,21",
"    </a>",
"    ]. However, an association between NTM cervicofacial lymphadenitis and interleukin (IL)-1B polymorphisms has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/29\">",
"     29",
"    </a>",
"    ]. Children with a history of bacille Calmette-Gu&eacute;rin (BCG) immunization appear to have a reduced risk of MAC lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oropharyngeal mucosa is the typical portal of entry for NTM cervical lymphadenitis. Lymphadenitis in other sites may follow penetrating trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,32\">",
"     10,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512912\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenitis is the most common manifestation of nontuberculous mycobacterial (NTM) disease in childhood. It typically occurs in children between one and five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,13,33\">",
"     10,13,33",
"    </a>",
"    ]. The cervicofacial nodes, particularly the submandibular nodes, are most frequently involved [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10\">",
"     10",
"    </a>",
"    ]. Lymph nodes outside the head and neck, including mediastinal nodes, may also be involved.",
"   </p>",
"   <p>",
"    NTM lymphadenitis generally presents as a unilateral, nontender node (&lt;4 cm in diameter) that slowly enlarges over several weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/34\">",
"     34",
"    </a>",
"    ]. The overlying skin gradually changes from pink to violaceous and thins to become parchment-like (",
"    <a class=\"graphic graphic_picture graphicRef69475 \" href=\"UTD.htm?40/60/41934\">",
"     picture 1",
"    </a>",
"    ) and may eventually suppurate through a sinus tract [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,10,34\">",
"     1,10,34",
"    </a>",
"    ]. Fever and other systemic findings are variable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. If prescribed, antibiotics directed against staphylococci or streptococci generally are not helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,19,34,35\">",
"     1,19,34,35",
"    </a>",
"    ]. These features do not reliably differentiate NTM from",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    lymphadenitis. (See",
"    <a class=\"local\" href=\"#H2272513023\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Delay in diagnosis is common. In a series of 105 patients, the time between onset of swelling and diagnosis was typically four to eight weeks (median 6.5 weeks, range eight days to two years) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10\">",
"     10",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The clinical features of NTM lymphadenitis have been described in several case series, each including &gt;100 children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,21,33\">",
"     10,21,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The submandibular nodes were involved in 87 percent, followed by preauricular (9 percent) and submental (3 percent) nodes; supraclavicular node involvement was uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nearly all cases are of cervical adenitis were unilateral (89 to 99 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,21,33\">",
"       10,21,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Violaceous discoloration and fluctuance were present in 85 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fever (T &gt;38.5&deg;C [101.3&deg;F]) was present in 21 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In one series, a fistula developed in 14 of 84 patients (16.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/21\">",
"       21",
"      </a>",
"      ]; in another, a draining sinus tract was noted on follow-up ultrasonography in 62 of 66 (93 percent) of patients who were initially treated with antibiotics, but without excision [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lymph nodes in addition to those in the cervicofacial region were involved in 15 percent of cases in one series (86 percent of such cases were caused by",
"      <em>",
"       M. haemophilum",
"      </em>",
"      , 14 percent by",
"      <em>",
"       M. avium",
"      </em>",
"      ) and 29 percent in another [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,33\">",
"       10,33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512920\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are not necessary in the routine evaluation of a child with suspected nontuberculous mycobacterial (NTM) adenitis, but may be helpful in evaluating other conditions in the differential diagnosis of cervical adenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasonographic features of NTM lymphadenitis were described in case series in which ultrasonography was performed 145 children who participated in a clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/33\">",
"     33",
"    </a>",
"    ]. Early in the disease course, decreased echogenicity was noted in all patients; in the advanced stages, 92 percent had intranodal liquefaction, matted nodes, and soft tissue edema.",
"   </p>",
"   <p>",
"    Computed tomography (CT) findings of NTM lymphadenitis include ring-enhancement with central hypodensity and minimal to absent fat stranding; the lack of fat stranding may help to differentiate NTM from pyogenic lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/33,37,38\">",
"     33,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiograph may be performed to look for signs of pulmonary tuberculosis or malignancy (eg, hilar adenopathy). The chest radiograph is typically normal in children with NTM lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,39\">",
"     2,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512928\">",
"    <span class=\"h1\">",
"     LABORATORY FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512935\">",
"    <span class=\"h2\">",
"     AFB stains and histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive staining for acid-fast bacilli (AFB) on samples of fistula drainage or biopsy specimens in children with nontuberculous mycobacterial (NTM) lymphadenitis is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/18,20,37\">",
"     18,20,37",
"    </a>",
"    ]. Negative AFB stains do not exclude mycobacterial disease and positive AFB stains do not distinguish NTM from",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H3#H3\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Microscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histopathologic features of NTM lymphadenitis include caseating granulomas, necrotizing granulomas, granulomatous and pyogenic inflammation, mononuclear inflammation, fibrocaseous reactions, multinucleated giant cells, and microabscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,37,40\">",
"     10,37,40",
"    </a>",
"    ]. These histologic features overlap with those of",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    . (See",
"    <a class=\"local\" href=\"#H2272513023\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512943\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with NTM lymphadenitis usually have normal complete blood count (CBC), differential, and erythrocyte sedimentation rate (ESR) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/16\">",
"     16",
"    </a>",
"    ]. Abnormal findings in the CBC",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated ESR should prompt consideration of other conditions in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512951\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2377830849\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of nontuberculous mycobacterial (NTM) lymphadenitis requires isolation of NTM from culture or polymerase chain reaction (PCR) of fistula drainage, tissue, or caseous material [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,10,16\">",
"     1,10,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2443738274\">",
"     'Microbiology/histopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among children with a negative culture or in whom culture results are pending, a presumptive diagnosis of NTM lymphadenitis can be made if the clinical (eg,",
"    <span class=\"nowrap\">",
"     subacute/chronic",
"    </span>",
"    nontender, unilateral lymphadenitis, violaceous discoloration)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histopathologic features (eg, positive stains for acid-fast bacilli [AFB], granulomas) are compatible with NTM and other conditions in the differential diagnosis (including",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    ) have been excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,10,16,37,41\">",
"     1,10,16,37,41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2272512912\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2272512928\">",
"     'Laboratory features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2272513023\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272512967\">",
"    <span class=\"h2\">",
"     Clinical suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;NTM should be suspected in young children (&lt;5 years) with",
"    <span class=\"nowrap\">",
"     subacute/chronic",
"    </span>",
"    (ie, &gt;3 weeks), unilateral, nontender, cervicofacial lymphadenitis that fails to improve or worsens despite antibiotic therapy directed against staphylococci and streptococci (if such therapy has been provided) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients are usually well appearing, without constitutional symptoms.",
"   </p>",
"   <p>",
"    The clinical course and appearance of NTM adenitis, particularly when the overlying skin becomes violaceous and thin, often is so characteristic that a presumptive diagnosis can be made based upon the history and physical examination (",
"    <a class=\"graphic graphic_picture graphicRef69475 \" href=\"UTD.htm?40/60/41934\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2272512912\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, early in the course of disease, particularly before the skin becomes violaceous, other conditions in the differential diagnosis may appear more likely, and evaluation and treatment for such conditions may be undertaken before NTM is suspected. This evaluation may include complete blood count (CBC) with differential and erythrocyte sedimentation rate (ESR), tuberculin skin testing (TST), interferon gamma release assay, imaging,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serologic testing (as clinically indicated for",
"    <em>",
"     Bartonella henselae",
"    </em>",
"    , Epstein-Barr virus, cytomegalovirus, human immunodeficiency virus, toxoplasmosis, etc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\", section on 'Subacute/chronic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2443737761\">",
"    <span class=\"h2\">",
"     Tuberculin skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;TST can help to narrow the differential diagnosis in a child with suspected NTM lymphadenitis, but the interpretation depends upon risk factors for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    and receipt of bacille Calmette-Gu&eacute;rin (BCG) vaccination.",
"   </p>",
"   <p>",
"    In children",
"    <strong>",
"     without",
"    </strong>",
"    risk factors for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    and who have not received BCG vaccination, TST with intermediate (5 tuberculin unit)",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    purified protein derivative (PPD) and &ge;5 mm induration at 48 hours supports a diagnosis of NTM infection. In a study of 174 children with cervicofacial lymphadenitis who had no exposure to",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    and had not received BCG vaccination, TST with &gt;5 mm of induration at 48 hours had a sensitivity, specificity, and positive and negative predictive value of 70 percent, 98 percent, 98 percent, and 64 percent, respectively for NTM (confirmed by positive culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polymerase chain reaction) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/12\">",
"     12",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    In children",
"    <strong>",
"     with",
"    </strong>",
"    risk factors for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    , TST &ge;5 mm does not distinguish between NTM and",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,12,36,42\">",
"     2,12,36,42",
"    </a>",
"    ]. TST &ge;15 mm may be more suggestive of",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    than NTM, but does not exclude NTM. In an observational study of 29 children with culture-confirmed NTM lymphadenitis, 17 (59 percent) had induration &ge;15 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/42\">",
"     42",
"    </a>",
"    ]. In children with suspected NTM lymphadenitis and TST &ge;5 mm induration, interferon gamma release assays (IGRA) testing may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2272513031\">",
"     'M. tuberculosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Independent of risk factors for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    , TST with &lt;5 mm of induration at 48 hours is not helpful in excluding mycobacterial disease. If NTM continues to be suspected in a child with negative TST, specimens should be obtained and sent for microbiologic and histopathologic studies. (See",
"    <a class=\"local\" href=\"#H2443738274\">",
"     'Microbiology/histopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2443738274\">",
"    <span class=\"h2\">",
"     Microbiology/histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue specimens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspirated fluid or pus should be sent for AFB stains, histopathology, and mycobacterial culture or PCR (in addition to bacterial and fungal stains and cultures, and cytopathology as clinically indicated).",
"   </p>",
"   <p>",
"    Isolation of NTM from culture or PCR of fistula drainage, tissue, or caseous material confirms the diagnosis of NTM lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"     2",
"    </a>",
"    ]. Pending culture results, positive AFB stains and characteristic histopathology can help to establish a presumptive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,10,16,37,41\">",
"     1,10,16,37,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Obtaining and processing specimens",
"    </strong>",
"    &ndash; Specimens for microbiologic and histopathologic studies in children with suspected NTM may be obtained through excisional biopsy, fine needle aspiration, or fistulous drainage. If there is a strong suspicion of NTM, excisional biopsy often is undertaken because it is curative; in addition the yield is usually better than with fine needle aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,2,8,37\">",
"     1,2,8,37",
"    </a>",
"    ]. However, some advocate fine needle aspiration for obtaining diagnostic material [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/13,41\">",
"     13,41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2272513047\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Incision and drainage generally are contraindicated if NTM is suspected because of the risk of recurrence or development of a chronically draining fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,44-47\">",
"     1,44-47",
"    </a>",
"    ]. However, incision and drainage may have been performed before NTM was suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is helpful to discuss specimen collection, transport, and processing with the microbiology laboratory before sending tissue or fluid samples for suspected NTM. Some species of NTM (eg,",
"    <em>",
"     M. haemophilum",
"    </em>",
"    ) have fastidious growth requirements.",
"   </p>",
"   <p>",
"    <strong>",
"     AFB stains and histopathology",
"    </strong>",
"    &ndash; Positive stains for AFB and histopathology with characteristic features (eg, granulomas, granulomatous and pyogenic inflammation, mononuclear inflammation, fibrocaseous reactions, multinucleated giant cells, and microabscesses) support a diagnosis of mycobacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,37,40\">",
"     10,37,40",
"    </a>",
"    ]. However, AFB staining cannot distinguish among NTM species or between NTM species and",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    . Negative AFB stains do not exclude mycobacterial disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H3#H3\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Microscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Culture",
"    </strong>",
"    &ndash; A positive culture confirms the diagnosis of NTM lymphadenitis. However, isolation and identification of the NTM species may take longer than six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/12\">",
"     12",
"    </a>",
"    ]. The yield of positive NTM cultures from excised lymph nodes ranges from 50 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. The yield is usually lower for specimens obtained through fine needle aspirate, though yields of up to 80 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microbiologic techniques to maximize the yield of NTM cultures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     PCR",
"    </strong>",
"    &ndash; The diagnosis of NTM infection can be established with species-specific or multiplex polymerase chain reaction (PCR) testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,48-50\">",
"     2,48-50",
"    </a>",
"    ]. PCR tests that can identify",
"    <em>",
"     M. avium",
"    </em>",
"    complex soon after growth is evident are commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/51\">",
"     51",
"    </a>",
"    ]. In a study of 67 children with mycobacterial adenitis and 50 children with cat scratch disease, the sensitivity and specificity of mycobacterial PCR were 72 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/48\">",
"     48",
"    </a>",
"    ]. The performance of PCR is based upon the quality of the specimen. Sending lymphatic tissue for culture and molecular testing is superior to sending exudative material; sending swabs of drainage is suboptimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513023\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of nontuberculous mycobacterial (NTM) lymphadenitis includes other infectious causes of unilateral lymphadenitis (eg,",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    ,",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    ,",
"    <em>",
"     B. henselae",
"    </em>",
"    ,",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    , viral infections, toxoplasmosis), benign cysts, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,10,39,52\">",
"     1,10,39,52",
"    </a>",
"    ]. Historical, examination, and laboratory findings (eg, blood counts, erythrocyte sedimentation rate, serology) may be helpful in differentiating NTM lymphadenitis from these conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513031\">",
"    <span class=\"h2\">",
"     M. tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is particularly important to try to distinguish between NTM and",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    lymphadenitis because they have different public health and treatment implications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"     2",
"    </a>",
"    ]. Culture is necessary for definitive diagnosis. (See",
"    <a class=\"local\" href=\"#H2443738274\">",
"     'Microbiology/histopathology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27768?source=see_link&amp;anchor=H5#H5\">",
"     \"Tuberculous lymphadenitis\", section on 'Cervical lymphadenopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No clinical or histopathologic feature reliably differentiates NTM from",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    lymphadenitis. However, in observational studies certain features were more suggestive of NTM [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/11,39,40\">",
"     11,39,40",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age (ie, preschool)",
"     </li>",
"     <li>",
"      Lack of risk factors for tuberculosis, including being born in a country with low prevalence of",
"      <em>",
"       M. tuberculosis",
"      </em>",
"     </li>",
"     <li>",
"      Normal chest radiograph",
"     </li>",
"     <li>",
"      Negative tuberculin skin testing (TST) results in family members",
"     </li>",
"     <li>",
"      Negative interferon-gamma release assay",
"     </li>",
"     <li>",
"      Ill-defined (nonpalisading), irregular, serpiginous, or sarcoid granulomas",
"     </li>",
"     <li>",
"      Polymorphonuclear leukocytes in center of areas of necrosis rather than diffusely scattered",
"     </li>",
"     <li>",
"      Lack of significant caseation",
"     </li>",
"     <li>",
"      Microabscesses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interferon gamma release assays (IGRA) may be helpful in differentiating NTM from",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    in children with TST &ge;5 mm at 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/43\">",
"     43",
"    </a>",
"    ]. A negative IGRA suggests NTM, whereas a positive IGRA suggests",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/36\">",
"     36",
"    </a>",
"    ].",
"    <em>",
"    </em>",
"    IGRAs do not cross-react with the NTM species that most frequently cause lymphadenitis (",
"    <em>",
"     M. avium",
"    </em>",
"    ,",
"    <em>",
"     M. haemophilum",
"    </em>",
"    , and",
"    <em>",
"     M. scrofulaceum",
"    </em>",
"    ), but they may cross-react with other species. Unfortunately, IGRAs often are indeterminate in children younger than five years, the predominant age group for NTM lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link&amp;anchor=H4850554#H4850554\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\", section on 'Assay antigens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link&amp;anchor=H365757238#H365757238\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\", section on 'Children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513039\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to lymphadenitis due to other bacterial pathogens, NTM lymphadenitis has a more",
"    <span class=\"nowrap\">",
"     subacute/chronic",
"    </span>",
"    course, lacks warmth and tenderness, and often has overlying violaceous skin discoloration; TST testing may be positive, but other laboratory findings usually are normal. (See",
"    <a class=\"local\" href=\"#H2272512912\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513047\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of nontuberculous mycobacterial (NTM) lymphadenitis in children may require surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antimycobacterial therapy, in combination or sequentially. When discussing the benefits and risks of these modalities, parents should be advised that clinical response to both surgical and medical management may be incomplete, and additional procedures and therapies may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513063\">",
"    <span class=\"h2\">",
"     Surgical excision",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2377831009\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with NTM or suspected NTM lymphadenitis and no evidence of pulmonary or disseminated disease, we suggest surgical excision without antimicrobial therapy as the initial intervention if excision can be performed safely (eg, without damage to the facial nerve (",
"    <a class=\"graphic graphic_figure graphicRef55677 \" href=\"UTD.htm?23/41/24218\">",
"     figure 1",
"    </a>",
"    )). Surgical excision is curative and provides the optimal specimen for diagnostic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,2,54-57\">",
"     1,2,54-57",
"    </a>",
"    ]. Incision and drainage generally are contraindicated because of the high probability of developing a chronically draining sinus tract, and increased risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,44-47\">",
"     1,44-47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2443738274\">",
"     'Microbiology/histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The management of pulmonary and disseminated NTM disease in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/282?source=see_link&amp;anchor=H1060354672#H1060354672\">",
"     \"Overview of nontuberculous mycobacterial pulmonary infections in children\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=see_link&amp;anchor=H564807864#H564807864\">",
"     \"Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized trial and observational studies, surgical excision has been associated with higher rates of cure,",
"    <span class=\"nowrap\">",
"     improved/more",
"    </span>",
"    rapid healing, better cosmetic results, and fewer adverse effects than curettage, antimicrobial therapy, or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/1,35,54,55,57,58\">",
"     1,35,54,55,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical and medical therapy of NTM lymphadenitis were compared in a trial in which 100 children were randomly assigned to surgical excision or antimicrobial therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"     rifabutin",
"    </a>",
"    for at least 12 weeks (and up to six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/55\">",
"     55",
"    </a>",
"    ].",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC) was isolated in 71 percent of children; none of the isolates was macrolide resistant. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of cure (defined as regression of the lymph node enlargement by at least 75 percent, cure of the fistula, and total skin closure without local recurrence or de novo lesions after six months) was greater in the patients treated with excision (96 versus 66 percent).",
"     </li>",
"     <li>",
"      Only 4 percent of children treated with surgical management had recurrence or development of new lesions; draining fistula developed in 32 percent of children treated with antibiotics.",
"     </li>",
"     <li>",
"      Surgical complications occurred in 28 percent of the surgical patients: staphylococcal wound infection in six, postoperative hematoma in one, temporary dysfunction of the marginal mandibular branch of the facial nerve in six, and permanent dysfunction of the marginal mandibular branch of the facial nerve in one; adverse effects related to medication or disease progression occurred in 78 percent of patients treated with antibiotics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a randomized trial comparing surgical excision and surgical curettage for NTM lymphadenitis in 50 children with culture- or polymerase chain reaction- (PCR) confirmed NTM lymphadenitis, wound healing was shorter with excision (3.6 versus 11.4 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/57\">",
"     57",
"    </a>",
"    ]. However, 16 percent of patients in the excision group had transient weakness of the facial nerve, compared with none of the patients who underwent curettage.",
"   </p>",
"   <p>",
"    Surgical excision of NTM lymphadenitis is recommended by the American Thoracic Society, Infectious Diseases Society of America, and the American Academy of Pediatrics Committee on Infectious Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513071\">",
"    <span class=\"h3\">",
"     Postoperative follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with isolated NTM lymphadenitis that has been successfully excised can be discharged from follow-up when their wound is healed. However, they should be informed that there is a small (&lt;5 percent) risk of recurrence or development of new lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/55\">",
"     55",
"    </a>",
"    ], and instructed to return to medical attention if they notice any changes in the lesion. Recurrences may be treated surgically or with antimycobacterial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513094\">",
"    <span class=\"h3\">",
"     Postoperative recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence to guide treatment of recurrent NTM lymphadenitis following surgical excision or antimicrobial therapy. In clinical trials and observational studies, recurrent NTM lymphadenitis has been successfully treated with surgical excision (if it can be performed safely) or antimycobacterial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513102\">",
"    <span class=\"h2\">",
"     Antimycobacterial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2377831016\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with isolated NTM lymphadenitis or suspected NTM lymphadenitis who are not candidates for surgical excision (eg, increased risk of facial nerve damage [eg, preauricular or intraparotid involvement (",
"    <a class=\"graphic graphic_figure graphicRef55677 \" href=\"UTD.htm?23/41/24218\">",
"     figure 1",
"    </a>",
"    )] or poor cosmetic result, established sinus tract, etc), we suggest antimicrobial therapy with or without subsequent gentle curettage rather than observation (ie, wait-and-see). The prolonged course of spontaneous resolution may make observation intolerable for many",
"    <span class=\"nowrap\">",
"     patients/parents",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/13,59\">",
"     13,59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2272513142\">",
"     'Observation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Randomized and observational studies indicate that antimicrobial therapy, usually with a macrolide and another agent, has moderate success in clearing the lymphadenitis without surgical excision (resolution rates range from 50 to 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/37,55,57,59-63\">",
"     37,55,57,59-63",
"    </a>",
"    ]. However, patients who are treated with antibiotics alone may develop fistulous sinus tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial comparing surgical excision with antimycobacterial therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"     rifabutin",
"    </a>",
"    for at least 12 weeks (and up to six months), 66 percent of patients treated with antibiotics were cured (defined as regression of the lymph node enlargement by at least 75 percent, cure of the fistula, and total skin closure without local recurrence or de novo lesions after six months), 32 percent developed draining fistula, and 78 percent had adverse effects related to medication or disease (eg, fever, fatigue, abdominal pain, tooth discoloration, headache, vomiting) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513110\">",
"    <span class=\"h3\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of NTM lymphadenitis is caused by",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In the United States,",
"    <em>",
"     M. simiae",
"    </em>",
"    and",
"    <em>",
"     M. fortuitum",
"    </em>",
"    are less common causes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <em>",
"     M. haemophilum",
"    </em>",
"    is more commonly isolated in the Netherlands and other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the predominance of MAC in pediatric cervicofacial lymphadenitis, when antimicrobial treatment for NTM lymphadenitis is undertaken, and",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    is not a concern, we suggest empiric therapy with a macrolide (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) in combination with either a rifamycin (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"     rifabutin",
"    </a>",
"    ) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"     ethambutol",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This regimen is suggested based upon those in randomized trials, observational studies, and in vitro studies; it is consistent with the recommendations of the American Thoracic Society, Infectious Diseases Society of America, and the American Academy of Pediatrics Committee on Infectious Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,8,37,55,60,62,63\">",
"     2,8,37,55,60,62,63",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    was used in early studies of MAC lymphadenitis; however,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    may be preferable because it is more palatable and is dosed once per day [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Although MAC is usually susceptible to macrolides, single-drug therapy with a macrolide increases the risk of development of mutational resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When antimicrobial therapy is undertaken in children with suspected NTM lymphadenitis in whom",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    remains a concern (eg, pending culture results in children with risk factors for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    , TST with &ge;15 mm of induration), the empiric antimicrobial regimen should include coverage for both NTM and",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    . One such regimen includes four drugs:",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and a macrolide (either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 2",
"    </a>",
"    ). The antibiotic regimen may need to be altered when definitive speciation is available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link&amp;anchor=H20#H20\">",
"     \"Tuberculosis disease in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antibiotic regimen may need to be altered if a species other than MAC is isolated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       <em>",
"        M. simiae",
"       </em>",
"      </strong>",
"      &ndash; The optimal therapeutic regimen for",
"      <em>",
"       M. simiae",
"      </em>",
"      has yet to be determined [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"       2",
"      </a>",
"      ]. Agents that appear to be active in vitro include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"       rifabutin",
"      </a>",
"      , clofazimine (not available in the United States),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=see_link\">",
"       streptomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <strong>",
"       <em>",
"        M. fortuitum",
"       </em>",
"      </strong>",
"      &ndash;",
"      <em>",
"       M. fortuitum",
"      </em>",
"      typically is susceptible to macrolides,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      , carbapenem, fluoroquinolones, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2,67-72\">",
"       2,67-72",
"      </a>",
"      ]. Single-agent therapy with a macrolide is not recommended because",
"      <em>",
"       M. fortuitum",
"      </em>",
"      has inducible macrolide resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       <em>",
"        M. haemophilum",
"       </em>",
"      </strong>",
"      &ndash; The optimal therapeutic regimen for",
"      <em>",
"       M. haemophilum",
"      </em>",
"      has yet to be determined [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"       2",
"      </a>",
"      ]. Agents that appear to be active in vitro include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , and rifamycins [",
"      <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/74-78\">",
"       74-78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2473624811\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimycobacterial agents that are used to treat NTM lymphadenitis often are difficult to tolerate and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=see_link\">",
"     streptomycin",
"    </a>",
"    , optic neuropathy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and hepatotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    . The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link\">",
"     \"Aminoglycosides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=see_link\">",
"     \"Ethambutol: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link\">",
"     \"Azithromycin, clarithromycin, and telithromycin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"     \"Rifampin and other rifamycins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=see_link\">",
"     \"Isoniazid: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513118\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of antimycobacterial therapy for lymphadenitis is unknown; patients typically are treated until their symptoms resolve (usually three to six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/16,55\">",
"     16,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513126\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to antimicrobial therapy for NTM lymphadenitis is monitored clinically. We suggest follow-up visits at approximately monthly intervals to ensure that patients are taking and tolerating their medications (if prescribed) and that their lymphadenitis is improving.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513134\">",
"    <span class=\"h3\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard definition for treatment failure. We consider patients who have no improvement of symptoms after six months of therapy or who have progression of symptoms during therapy to have treatment failure.",
"   </p>",
"   <p>",
"    For children who are not responding to what should be effective therapy it is important to verify speciation and susceptibility testing and to make sure that the child has received antimycobacterial therapy as prescribed.",
"   </p>",
"   <p>",
"    Surgical excision, if it can be safely performed, may be warranted for patients who fail to improve or worsen during antimicrobial therapy for NTM lymphadenitis. (See",
"    <a class=\"local\" href=\"#H2272513063\">",
"     'Surgical excision'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who are not surgical candidates, a change in the antimicrobial regimen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    testing for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513142\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not usually suggest observation for children with NTM lymphadenitis. Given enough time, children with isolated NTM lymphadenitis will have resolution of disease without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/13,52,59\">",
"     13,52,59",
"    </a>",
"    ]. However, many children with untreated NTM lymphadenitis develop sinus tracts with prolonged drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/10,59\">",
"     10,59",
"    </a>",
"    ]. Most",
"    <span class=\"nowrap\">",
"     parents/patients",
"    </span>",
"    are not willing to tolerate an unsightly, potentially draining lesion on the face or neck for the six months (or longer) that may be required for spontaneous healing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic therapy (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"     rifabutin",
"    </a>",
"    for 12 weeks) and observation were compared in a small randomized trial in 50 immunocompetent children with advanced NTM lymphadenitis (defined by fluctuance and skin discoloration and microbiologically confirmed by culture or PCR of fine needle aspirates) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/59\">",
"     59",
"    </a>",
"    ]. The median time to resolution (regression of the lymph node enlargement by &ge;75 percent, cured fistula and total skin closure, and lack of recurrence or de novo lesions) was similar between groups (36 versus 40 weeks in the treatment and observation groups, respectively). In follow-up of at least two years, no recurrences were reported. Although these findings suggest that antimicrobial therapy may provide no benefit over observation, the study may have been underpowered to detect a difference. Another limitation is the relatively short duration of antimicrobial therapy.",
"   </p>",
"   <p>",
"    In an observational study in 92 children who had NTM cervical lymphadenitis and minimal disease (the majority had involvement of only one node, and only one quarter had overlying skin changes), purulent drainage lasted three to five weeks in 84 children (91 percent) and eight weeks in five children (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/42/13994/abstract/13\">",
"     13",
"    </a>",
"    ]. Seventy-one percent of the children had complete resolution of the symptoms in three to six months, 25 percent within nine months, and 2 percent within 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272513150\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphadenitis is the most common manifestation of nontuberculous mycobacterial (NTM) disease in otherwise healthy children. (See",
"      <a class=\"local\" href=\"#H2272512883\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of cases of NTM lymphadenitis are caused by",
"      <em>",
"       Mycobacterium avium",
"      </em>",
"      complex (MAC). Other commonly isolated species include",
"      <em>",
"       M. haemophilum, M. simiae",
"      </em>",
"      , and",
"      <em>",
"       M. fortuitum",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H2272512896\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NTM lymphadenitis typically occurs in immune-competent children between one and five years of age and involves the cervicofacial lymph nodes. It typically begins as a unilateral, nontender, node that slowly enlarges over several weeks, during which fluctuance, violaceous discoloration, thinning of the overlying skin, and sinus drainage may develop (",
"      <a class=\"graphic graphic_picture graphicRef69475 \" href=\"UTD.htm?40/60/41934\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2272512912\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with NTM lymphadenitis usually have normal complete blood count, differential, erythrocyte sedimentation rate, and chest radiograph. (See",
"      <a class=\"local\" href=\"#H2272512928\">",
"       'Laboratory features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2272512920\">",
"       'Radiographic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive diagnosis requires isolation of NTM from culture or polymerase chain reaction of fistula drainage, tissue, or caseous material. In the absence of isolation of NTM, a presumptive diagnosis can be made if the clinical (eg,",
"      <span class=\"nowrap\">",
"       subacute/chronic",
"      </span>",
"      unilateral lymphadenitis, violaceous discoloration)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      histopathologic features (eg, positive acid-fast bacilli [AFB] stains, granulomas) are compatible with NTM and other conditions in the differential diagnosis (including",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      ) have been excluded. (See",
"      <a class=\"local\" href=\"#H2272512951\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of NTM lymphadenitis includes other infectious causes of unilateral lymphadenitis, benign cysts, and malignancy. A combination of clinical, radiographic, and laboratory findings (including serology and microbiologic testing) may be necessary to distinguish NTM lymphadenitis from these conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link\">",
"       \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"       \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of NTM lymphadenitis in children may require surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antimycobacterial therapy, in combination or sequentially (see",
"      <a class=\"local\" href=\"#H2272513047\">",
"       'Management'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with isolated NTM or suspected NTM lymphadenitis, we suggest surgical excision without antimicrobial therapy the initial intervention if excision can be performed safely (eg, without damage to the facial nerve) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2272513063\">",
"       'Surgical excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with NTM who are not candidates for surgical excision, we suggest antimicrobial therapy with or without gentle curettage (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2272513102\">",
"       'Antimycobacterial therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Given the predominance of MAC, pending culture results, we usually treat with a macrolide (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      ) in combination with another agent (either a rifamycin or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       ethambutol",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 2",
"      </a>",
"      ). The optimal duration of therapy is unknown; patients typically are treated until their symptoms resolve (usually three to six months). (See",
"      <a class=\"local\" href=\"#H2272513102\">",
"       'Antimycobacterial therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/1\">",
"      Fraser L, Moore P, Kubba H. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. Otolaryngol Head Neck Surg 2008; 138:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/2\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/3\">",
"      Bolan G, Reingold AL, Carson LA, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis 1985; 152:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/4\">",
"      Celdr&aacute;n A, Esteban J, Ma&ntilde;as J, Granizo JJ. Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair. J Hosp Infect 2007; 66:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/5\">",
"      Ferguson DD, Gershman K, Jensen B, et al. Mycobacterium goodii infections associated with surgical implants at Colorado hospital. Emerg Infect Dis 2004; 10:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/6\">",
"      McNabb A, Eisler D, Adie K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/7\">",
"      Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Diseases caused by nontuberculous mycobacteria: (atypical mycobacteria, mycobacteria other than Mycobacterium tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.759.",
"    </li>",
"    <li>",
"     Mycobacterium. In: List of Prokaryotic names with Standing in Nomenclature. file://www.bacterio.cict.fr/m/mycobacterium.html (Accessed on July 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/10\">",
"      Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/11\">",
"      Cruz AT, Ong LT, Starke JR. Mycobacterial infections in Texas children: a 5-year case series. Pediatr Infect Dis J 2010; 29:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/12\">",
"      Lindeboom JA, Kuijper EJ, Prins JM, et al. Tuberculin skin testing is useful in the screening for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis 2006; 43:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/13\">",
"      Zeharia A, Eidlitz-Markus T, Haimi-Cohen Y, et al. Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone. Pediatr Infect Dis J 2008; 27:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/14\">",
"      Cohen YH, Amir J, Ashkenazi S, et al. Mycobacterium haemophilum and lymphadenitis in immunocompetent children, Israel. Emerg Infect Dis 2008; 14:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/15\">",
"      Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008; 14:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/16\">",
"      Chesney PJ. Nontuberculous mycobacteria. Pediatr Rev 2002; 23:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/17\">",
"      Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/18\">",
"      Pham-Huy A, Robinson JL, Tapi&eacute;ro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health 2010; 15:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/19\">",
"      Vu TT, Daniel SJ, Quach C. Nontuberculous mycobacteria in children: a changing pattern. J Otolaryngol 2005; 34 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/20\">",
"      Blyth CC, Best EJ, Jones CA, et al. Nontuberculous mycobacterial infection in children: a prospective national study. Pediatr Infect Dis J 2009; 28:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/21\">",
"      Reuss AM, Wiese-Posselt M, Weissmann B, et al. Incidence rate of nontuberculous mycobacterial disease in immunocompetent children: a prospective nationwide surveillance study in Germany. Pediatr Infect Dis J 2009; 28:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/22\">",
"      Haverkamp MH, Arend SM, Lindeboom JA, et al. Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis 2004; 39:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/23\">",
"      Mangione EJ, Huitt G, Lenaway D, et al. Nontuberculous mycobacterial disease following hot tub exposure. Emerg Infect Dis 2001; 7:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/24\">",
"      Stout JE, Gadkowski LB, Rath S, et al. Pedicure-associated rapidly growing mycobacterial infection: an endemic disease. Clin Infect Dis 2011; 53:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/25\">",
"      Lee WJ, Kim TW, Shur KB, et al. Sporotrichoid dermatosis caused by Mycobacterium abscessus from a public bath. J Dermatol 2000; 27:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/26\">",
"      von Baum H, Bommer M, Forke A, et al. Is domestic tap water a risk for infections in neutropenic patients? Infection 2010; 38:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/27\">",
"      Fleming GA, Frangoul H, Dermody TS, Halasa N. A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. Pediatr Infect Dis J 2006; 25:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/28\">",
"      Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 2005; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/29\">",
"      Haverkamp MH, Lindeboom JA, de Visser AW, et al. Nontuberculous mycobacterial cervicofacial lymphadenitis in children from the multicenter, randomized, controlled trial in The Netherlands: relevance of polymorphisms in candidate host immunity genes. Int J Pediatr Otorhinolaryngol 2010; 74:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/30\">",
"      Romanus V, Hallander HO, W&aring;hl&eacute;n P, et al. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis 1995; 76:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/31\">",
"      Katila ML, Brander E, Backman A. Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood. Tubercle 1987; 68:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/32\">",
"      Holland AJ, Holland J, Martin HC, et al. Noncervicofacial atypical mycobacterial lymphadenitis in childhood. J Pediatr Surg 2001; 36:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/33\">",
"      Lindeboom JA, Smets AM, Kuijper EJ, et al. The sonographic characteristics of nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Radiol 2006; 36:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/34\">",
"      Penn R, Steehler MK, Sokohl A, Harley EH. Nontuberculous mycobacterial cervicofacial lymphadenitis--a review and proposed classification system. Int J Pediatr Otorhinolaryngol 2011; 75:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/35\">",
"      Suskind DL, Handler SD, Tom LW, et al. Nontuberculous mycobacterial cervical adenitis. Clin Pediatr (Phila) 1997; 36:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/36\">",
"      Staufner C, Sommerburg O, Holland-Cunz S. Algorithm for early diagnosis in nontuberculous mycobacterial lymphadenitis. Acta Paediatr 2012; 101:e382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/37\">",
"      Hazra R, Robson CD, Perez-Atayde AR, Husson RN. Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy. Clin Infect Dis 1999; 28:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/38\">",
"      Robson CD, Hazra R, Barnes PD, et al. Nontuberculous mycobacterial infection of the head and neck in immunocompetent children: CT and MR findings. AJNR Am J Neuroradiol 1999; 20:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/39\">",
"      Carvalho AC, Codecasa L, Pinsi G, et al. Differential diagnosis of cervical mycobacterial lymphadenitis in children. Pediatr Infect Dis J 2010; 29:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/40\">",
"      Kraus M, Benharroch D, Kaplan D, et al. Mycobacterial cervical lymphadenitis: the histological features of non-tuberculous mycobacterial infection. Histopathology 1999; 35:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/41\">",
"      Tunkel DE, Romaneschi KB. Surgical treatment of cervicofacial nontuberculous mycobacterial adenitis in children. Laryngoscope 1995; 105:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/42\">",
"      Haimi-Cohen Y, Zeharia A, Mimouni M, et al. Skin indurations in response to tuberculin testing in patients with nontuberculous mycobacterial lymphadenitis. Clin Infect Dis 2001; 33:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/43\">",
"      Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/44\">",
"      Iversen RH, Illum P. Cervicofacial nontuberculous mycobacterial lymphadenitis in children. Dan Med J 2012; 59:A4349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/45\">",
"      Spyridis P, Maltezou HC, Hantzakos A, et al. Mycobacterial cervical lymphadenitis in children: clinical and laboratory factors of importance for differential diagnosis. Scand J Infect Dis 2001; 33:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/46\">",
"      Scott CA, Atkinson SH, Sodha A, et al. Management of lymphadenitis due to non-tuberculous mycobacterial infection in children. Pediatr Surg Int 2012; 28:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/47\">",
"      Taha AM, Davidson PT, Bailey WC. Surgical treatment of atypical mycobacterial lymphadenitis in children. Pediatr Infect Dis 1985; 4:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/48\">",
"      Bruijnesteijn Van Coppenraet ES, Lindeboom JA, Prins JM, et al. Real-time PCR assay using fine-needle aspirates and tissue biopsy specimens for rapid diagnosis of mycobacterial lymphadenitis in children. J Clin Microbiol 2004; 42:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/49\">",
"      Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, et al. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev 2011; 24:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/50\">",
"      Richardson ET, Samson D, Banaei N. Rapid Identification of Mycobacterium tuberculosis and nontuberculous mycobacteria by multiplex, real-time PCR. J Clin Microbiol 2009; 47:1497.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.gen-probe.com/products-services/culture-identification (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/52\">",
"      Mandell DL, Wald ER, Michaels MG, Dohar JE. Management of nontuberculous mycobacterial cervical lymphadenitis. Arch Otolaryngol Head Neck Surg 2003; 129:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/53\">",
"      Haustein T, Ridout DA, Hartley JC, et al. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 2009; 28:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/54\">",
"      Panesar J, Higgins K, Daya H, et al. Nontuberculous mycobacterial cervical adenitis: a ten-year retrospective review. Laryngoscope 2003; 113:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/55\">",
"      Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, et al. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 44:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/56\">",
"      Starke JR. Commentary: The natural history of nontuberculous mycobacterial cervical adenitis. Pediatr Infect Dis J 2008; 27:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/57\">",
"      Lindeboom JA. Surgical treatment for nontuberculous mycobacterial (NTM) cervicofacial lymphadenitis in children. J Oral Maxillofac Surg 2012; 70:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/58\">",
"      Lindeboom JA, Lindeboom R, Bruijnesteijn van Coppenraet ES, et al. Esthetic outcome of surgical excision versus antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Infect Dis J 2009; 28:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/59\">",
"      Lindeboom JA. Conservative wait-and-see therapy versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis 2011; 52:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/60\">",
"      Berger C, Pfyffer GE, Nadal D. Treatment of nontuberculous mycobacterial lymphadenitis with clarithromycin plus rifabutin. J Pediatr 1996; 128:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/61\">",
"      Coulter JB, Lloyd DA, Jones M, et al. Nontuberculous mycobacterial adenitis: effectiveness of chemotherapy following incomplete excision. Acta Paediatr 2006; 95:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/62\">",
"      Luong A, McClay JE, Jafri HS, Brown O. Antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis. Laryngoscope 2005; 115:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/63\">",
"      Timmerman MK, Morley AD, Buwalda J. Treatment of non-tuberculous mycobacterial cervicofacial lymphadenitis in children: critical appraisal of the literature. Clin Otolaryngol 2008; 33:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/64\">",
"      Steele RW, Thomas MP, B&eacute;gu&eacute; RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J 2001; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/65\">",
"      Matsui D, Lim R, Tschen T, Rieder MJ. Assessment of the palatability of beta-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med 1997; 151:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/66\">",
"      van Ingen J, Totten SE, Heifets LB, et al. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012; 39:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/67\">",
"      Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/68\">",
"      Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/69\">",
"      Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/70\">",
"      Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/71\">",
"      Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/72\">",
"      Wallace RJ Jr, Bedsole G, Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/73\">",
"      Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/74\">",
"      Kiehn TE, White M. Mycobacterium haemophilum: an emerging pathogen. Eur J Clin Microbiol Infect Dis 1994; 13:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/75\">",
"      Atkinson BA, Bocanegra R, Graybill JR. Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Antimicrob Agents Chemother 1995; 39:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/76\">",
"      McBride ME, Rudolph AH, Tschen JA, et al. Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections. Arch Dermatol 1991; 127:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/77\">",
"      Kristjansson M, Bieluch VM, Byeff PD. Mycobacterium haemophilum infection in immunocompromised patients: case report and review of the literature. Rev Infect Dis 1991; 13:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/42/13994/abstract/78\">",
"      Plemmons RM, McAllister CK, Garces MC, Ward RL. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. Clin Infect Dis 1997; 24:995.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86045 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13994=[""].join("\n");
var outline_f13_42_13994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2272513150\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512883\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512896\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512904\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512912\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512920\">",
"      RADIOGRAPHIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512928\">",
"      LABORATORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512935\">",
"      AFB stains and histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512943\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512951\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2377830849\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2272512967\">",
"      Clinical suspicion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2443737761\">",
"      Tuberculin skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2443738274\">",
"      Microbiology/histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513023\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513031\">",
"      M. tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513039\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513047\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513063\">",
"      Surgical excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2377831009\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513071\">",
"      - Postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513094\">",
"      - Postoperative recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513102\">",
"      Antimycobacterial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2377831016\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513110\">",
"      - Regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2473624811\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513118\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513126\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513134\">",
"      - Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513142\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2272513150\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/86045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/86045|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/41/24218\" title=\"figure 1\">",
"      Facial nerve anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/86045|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/60/41934\" title=\"picture 1\">",
"      Mycobacterium avium adenitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/86045|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/4/8271\" title=\"table 2\">",
"      Treatment NTM children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=related_link\">",
"      Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=related_link\">",
"      Etiology and clinical manifestations of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=related_link\">",
"      Isoniazid: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=related_link\">",
"      Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/282?source=related_link\">",
"      Overview of nontuberculous mycobacterial pulmonary infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7722?source=related_link\">",
"      Overview of nontuberculous mycobacterial skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27768?source=related_link\">",
"      Tuberculous lymphadenitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_42_13995="Self-report measures for specific phobia by phobia subtype";
var content_f13_42_13995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F65262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F65262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Self-report measures for specific phobia by phobia subtype",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Measure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Blood-Injection-Injury",
"       </td>",
"       <td>",
"        Mutilation Questionnaire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical Fear Survey",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood-Injection Symptom Scale",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Situational",
"       </td>",
"       <td>",
"        Claustrophobia Questionnaire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dental Anxiety Inventory",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Natural environment",
"       </td>",
"       <td>",
"        Acrophobia Questionnaire",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Animal",
"       </td>",
"       <td>",
"        Snake Questionnaire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fear of Spiders Questionnaire",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13995=[""].join("\n");
var outline_f13_42_13995=null;
var title_f13_42_13996="AUDIT-C";
var content_f13_42_13996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AUDIT-C",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Question #1: How often did you have a drink containing alcohol in the past year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Never",
"       </td>",
"       <td>",
"        (0 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Monthly or less",
"       </td>",
"       <td>",
"        (1 point)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Two to four times a month",
"       </td>",
"       <td>",
"        (2 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Two to three times per week",
"       </td>",
"       <td>",
"        (3 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Four or more times a week",
"       </td>",
"       <td>",
"        (4 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Question #2: How many drinks did you have on a typical day when you were drinking in the past year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; 1 or 2",
"       </td>",
"       <td>",
"        (0 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; 3 or 4",
"       </td>",
"       <td>",
"        (1 point)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; 5 or 6",
"       </td>",
"       <td>",
"        (2 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; 7 to 9",
"       </td>",
"       <td>",
"        (3 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; 10 or more",
"       </td>",
"       <td>",
"        (4 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Question #3: How often did you have six or more drinks on one occasion in the past year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Never",
"       </td>",
"       <td>",
"        (0 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Less than monthly",
"       </td>",
"       <td>",
"        (1 point)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Monthly",
"       </td>",
"       <td>",
"        (2 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Weekly",
"       </td>",
"       <td>",
"        (3 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Daily or almost daily",
"       </td>",
"       <td>",
"        (4 points)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The AUDIT-C is scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13996=[""].join("\n");
var outline_f13_42_13996=null;
var title_f13_42_13997="Risk ERCP complications";
var content_f13_42_13997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for overall complications of endoscopic retrograde cholangiopancreatography (ERCP) identified by multivariate analysis in large studies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Object of the study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Post-procedure complications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Independent risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Freeman et al 1996",
"       </td>",
"       <td rowspan=\"5\">",
"        Prospective multicenter study",
"       </td>",
"       <td rowspan=\"5\">",
"        Biliary sphincterotomy",
"       </td>",
"       <td rowspan=\"5\">",
"        2347 patients",
"       </td>",
"       <td rowspan=\"5\">",
"        9.8 percent",
"       </td>",
"       <td>",
"        Difficulty of cannulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precut sphincterotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percutaneous-endoscopic procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sphincter of Oddi dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Loperfido et al 1998",
"       </td>",
"       <td rowspan=\"2\">",
"        Prospective multicenter study",
"       </td>",
"       <td rowspan=\"2\">",
"        Diagnostic and therapeutic ERCP",
"       </td>",
"       <td rowspan=\"2\">",
"        2769 patients",
"       </td>",
"       <td rowspan=\"2\">",
"        4.0 percent",
"       </td>",
"       <td>",
"        Small center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precut sphincterotomy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Masci et al 2001",
"       </td>",
"       <td rowspan=\"3\">",
"        Prospective multicenter study",
"       </td>",
"       <td rowspan=\"3\">",
"        Diagnostic and therapeutic ERCP",
"       </td>",
"       <td rowspan=\"3\">",
"        2444 procedures",
"       </td>",
"       <td rowspan=\"3\">",
"        4.9 percent",
"       </td>",
"       <td>",
"        Age under 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precut sphincterotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failed clearing of biliary stones",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Christensen et al 2004",
"       </td>",
"       <td rowspan=\"3\">",
"        Prospective monocenter study",
"       </td>",
"       <td rowspan=\"3\">",
"        Diagnostic and therapeutic ERCP",
"       </td>",
"       <td rowspan=\"3\">",
"        1177 patients",
"       </td>",
"       <td rowspan=\"3\">",
"        15.9 percent",
"       </td>",
"       <td>",
"        Dilated bile duct",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placement of stent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;40 mg of hyoscine-N-butyl bromide",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Williams et al 2008",
"       </td>",
"       <td rowspan=\"3\">",
"        Prospective multicenter study",
"       </td>",
"       <td rowspan=\"3\">",
"        Diagnostic and therapeutic ERCP",
"       </td>",
"       <td rowspan=\"3\">",
"        4561 patients",
"       </td>",
"       <td rowspan=\"3\">",
"        5 percent",
"       </td>",
"       <td>",
"        Difficult cannulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precut sphincterotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sphincter of Oddi dysfunction",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Wang et al 2009",
"       </td>",
"       <td rowspan=\"5\">",
"        Prospective multicenter study",
"       </td>",
"       <td rowspan=\"5\">",
"        Diagnostic and therapeutic ERCP",
"       </td>",
"       <td rowspan=\"5\">",
"        2691 patients",
"       </td>",
"       <td rowspan=\"5\">",
"        7.9 percent",
"       </td>",
"       <td>",
"        Female sex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periampullary diverticulum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficult cannulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic cannulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precut sphincterotomy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Cotton et al 2009",
"       </td>",
"       <td rowspan=\"2\">",
"        Retrospective multicenter study",
"       </td>",
"       <td rowspan=\"2\">",
"        Diagnostic and therapeutic ERCP",
"       </td>",
"       <td rowspan=\"2\">",
"        2691 procedures",
"       </td>",
"       <td rowspan=\"2\">",
"        4.0 percent",
"       </td>",
"       <td>",
"        Sphincter of Oddi dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary sphincterotomy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ERCP: endoscopic retrograde cholangiopancreatography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13997=[""].join("\n");
var outline_f13_42_13997=null;
var title_f13_42_13998="TMLR event free survival";
var content_f13_42_13998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Cardiac event-free survival in refractory angina is better with transmyocardial laser revascularization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 309px; background-image: url(data:image/gif;base64,R0lGODlhxgE1AeYAAP///4CAgAAAAICzmUBAQABmM8DAwP+AgICZ/0CMZqCgoHBwcNDQ0CAgIBAQEPDw8DAwMMDZzQAz/1BQUMDN/0Bm///AwP8AABBwQPD28yB5TVCWc7CwsJCQkODg4KDGs3CpjWBgYNDj2bDQwODs5hBA/5C8pjCDWWCggP9AQCBN//8gIKCz/2CA//+goODm//Dz/9DZ/3CN//8wMFBz///w8P9QULDA//8QEP/Q0P/g4P9gYJCm/zBZ//+wsP+QkP9wcECJczBpv4CmzK8PT+8GA9Dd8nA8r2CG5SBGMr98r6DAzHB2c088SXCmmWBQMCBZfEBZTQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADGATUBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLAhKwMMBj1QEEDBg0EcAnTw4LCjR0MMAgggMAjCSAEQBC1A6cABx48wHRIQMFIQBwETAEwQwOGBAAcAOghYELMoQwM1AYgMoFRAAKQkoQoyEKCqVQNGs/qT2pTpUqlcqVoNQICp1rP5uAolurIDA5QA/27mPBQgyhAKaPPOYyAUgoEHHgQ0MNBAAMfCHHYqQBQgSZMjeiO/m0lTAFYFhRssBsDApAOijJk8KWKjhuTTBauigEIEhwXUsAFWFYGhhBIcQEzH3p2vKgANQirUSLHiNe/j9HybCFIC7w/cupFLb+c7QwEkLQTpIG58und0vgGgcFLixaDnB76rLxd+hIYW2Qdtn5Fjvf1v4X8vkWCe0IEL6d0nYDb5DYACfIbkMAN9AzZITX4kFGBECTAc8l+ADmbYTH4AbGBCCwggomAKOmhoYjIcfnACBRQmcgAOP5woIzEcAoCBCBWEmIgFK5A444++1AgCCiwuUgMQMAKpZP8uNZKAQQYVsMAIjylEt+SVsNQIwAkf3KBCI0fi4AOWZLqi5QcJAKCClI1YgENpZcaJipYZYEACC186UoMNOBxggZVyBtqJluKBoOYNkPhgQwoX4JACED/8KeiklxAagQYAsFABJTpYcIANM1zQ4wEudEfpqYsQ+tsIADSXSQ4+fLqCqDYc4EN9qOY6iKombAAAApt6YoELBxB3wQy1WlCiroKqah0JMLgqSg0W/ABECjhckMIOLizL7JWqdmjCr/GdQu2nxwKB67c/huseANH2t4oPO6yAww4+AMpug+H+FgEACL6Sww+hpvCDt/sK2K+BALzAnyw1uMDnCkCYmvD/d/1GmAHA5c5iARD22uCCvhfv1i8ACXzQcIu36PADozP8sG7JsZ2soiAg7lIDvTisgC/NsJ1sowgAsFhhLzkAUbALQEcm9JCC5BiMDi6ssALTTYvDwEuyCE2bIEUOU/XVWXdDQAg3CRBR12YtwmXUbIptNdZlY8MTAQ1AEMIsQgOApiBeHjM23XVTY5kDIZDlyUQaXQQA4xYl0vezgqyJzOCFUwNBYR2EQBInD5g0kwMXiQ4XY20vgsIAguCpDOaZQ2OAAxB44EAHnSCV0kwGyKUTT6g7cukgKiD6+tyxO7O1IMuDbtLmey/V1VRjkZX6Ihqwmmmwy8CefDJlCaI4/+ghOFAYBA9ILz0AYlkVviO9DiItM95/PwwDBJhPQP6fbyIUUzvRyFAA0JbgOUJjggAWNOpnv18gpTI/4UAnFIASA5hEAYEZTGG4Voi+DcJDgogWXhaIvAYGYwGbAcUCHCAYs2BGMCk0hAcF8a4EduwZDDShKyaQEttd73EdsEoMXzFDQWjgX/AqDzXGFikdvgJ4BOzfIChDEykS8YeLgBrObhgNiYVqBckimRNDAcUFWBEAFTQARPiGRUU4aWMNexg2hnUtUaXAVggboycm8JkCFgICbbyiJFI2iIBxIwfEwpajSDUzPWKCAYVBieMIsYAGCJGNkriZIF7AMnDoIP9WxnpUqe6TAwuY0pQ5oFZ3TGmaUkZHlaaUxRoPQcWkxKKIg7hRIXVUjnPZYFYz4FYeecOoCxhTWxYwZn1cYMzXMGqVx2zUMFHxgCBWZYicUaMa13bLQCoCBYYCWyfTUS0bHOsAjYRNKXdwgR1YoJTG3AEAQnUBZ9ZzEMlMAQDYiaFV7KQyZ4xLADwQAG5myZuJ+NogpPYOelntZ7y5kCCSOSuK3vOZ+NQWAMxJOFUMxTLvoyRNDDCBvbGNEm8T5zxycIBQiWyaaJEoAJL5ojdhFKMTjaY8XXE4gp4RcX4ZXzcpEb+Fxk0eVDPnDNApGZnSFAgX8MFN75nTGTDKBq//cIACJtAAB5wRpAbwHCYnQTnA5ekeDvXZmGIKoJwegFoAmOoODnCATmmrBtmKUSsUoAAGtMSggiDA5naCu5NSYnWEUAGIEHADCjjWsfJ6B0td2q2sOLWtgpjqMU2pUR80Kp2z8CtN0DfWSQxvEDdAgGorwNrWlkACsIVtCVrbWtXK4KjhSOo5QZu1gVLkkoeYZWknkb1JvOCxjk2talVQgRGWI60QrRtIISjFvzBAm8I9qCUY1gkElIAGkSXHZC9Qq0jFsmTWxa5BpwvQ4UoCgZ2AAQIk0IKjnYNqB9hBClJAz2Ptd64HMK/FyoRdbRrUt2PBZitwaQgQfuIFLSgB/wLs645T/oCu+uXvMa26Lbr6yZQwFRAE21sIBWAlLhI0bCVqCAoKVMBy/LAwXa+132wZk8O1omupziudqjQgcQFoAGgI8T4zuncSuhSFl3rgXIOcklh0XZSGjemo/QLBw1jOspa3zOUue/nLYObywZphGfHNZSojxsmRJaHFUbBgtjEwSqdMGeY62/nOeO7yxISZDNr1DgJSxJ/+CDABwJoJoY14YynkW4IWhNeRhRjYnvNVDApWJsWEMPEtGHyIBIzLFBCWMIUhfQhPwQwIlA5GSAp6iGoCd6iYGAEGQADHUsSgAiXALakR4alQLXXAuFjAkA/xzyqumawJOAHRTv9BgR4Ub9dg8oHStOUnXYg1ER81QEi1uwkTFODTp8BTc6GtJ4e+SWa26IADXj2IngqV25sQwQkSUOtFe9fR5H4E1er1JmCzopY/3WpXA8oKTi8iAyDAgPZOAYMWSGDC+YaEy/y9iusa2BB89asDDL1gRFNC1rROxQtoIOGIE8PV12x1dmH9iQwke9mocPGaRm3yXRTbloOwtCSP3e1vr0JTEugBDx5dc1tke9uCMF8AVmJSlodC3vReBQxYQIOgD73ouHD3T09sZBWLAuEKbwUMbhDhHsggzlifhVa56lUZLkCNIZjAygvucU2AvN6rIHsJVHD2tMMi4381RC2NDe//Urhc2bG4gQxUwHfj+V0VHsDKA/6C8epVpBOMMwvkJinDunPC2+CGRQwW32jHP74UEMjJA36sCtHiTRCmS4kBUwF1vL9i9D0oPc1P34kyK4XgoigMN323E0x30POdAPvCZ/ECHvRAAjRgwe55j4nbCWICZzbFWxpQmJyozynUGwvSU3H3WzT/+TRAAAXQTn1MhAAlFyTEQEehOwsKgCLgX1/7qjL+VBwe5rYwdTLwYhLAXDKgfuzXfo/wAO/3GYUAUsgXCW9BEkuxFgQkAIXVebEAer4QAxSAAAOoAgVYAQe4fgpICeYzaAQwbJqAGCZhABlEGIYxe69Qe8PggSBI/4AGiIAnyAgKwELU5Qmd8ROb8UKaITkR+HUJpzLIgIMhOIIHqFosgFyONX1Yh0KbloSjMAInMGsk0Aw4qFoIQAO0xVqxdYZlWAHpp1o80GRAQ3mNMHeCZAsigAIYQEjdAANUSAEsIIYtIIIkyAJExyyWgYWJIFo753W1kAEqggED8IXnoIfAUgKzpX5WKCg40QBlkXKFwH1Lhzg8NwsRgAIFsAHLdw4vwAIDWIAt0Ia5shIj9lUn9m5zyAsZYAIaoAGP2A4UwAN/KAGBOIhX0hkhcHGdKHccoDeheAujWAAogETtIIm4VokUcIk/IocAoHMbt4y4QAIDkIsmYHvrkP+Kq6gC0YcliEhaIKERHFR4wjACG+CM0BgPvchcbigjnrhCTccLBkcL3ogBXCKO7MBo+PYjvkeLutCPtoAmGIACAPgOoQZx+IiMyhgkWqgLJJBwJzCP7yBzutYg2mhomoZi3EgMA3AC9SBu9zgMzYcA0ncOIbERtGQWXed0zZBk80CQwtgLLICG8PBAEJR9tegMbUYPEWmNuOAwrhIDIeKSTAkvA9gCaHcDZNgCeEGVFWCVABADLUCCFcIDOoIAPAAvwEIDiPIC6ncDH4kLgqaJhMZxdBcNinYPHikMPCABMlAIEvBaEgAAuYcAuZeK0DeGLjmY6cdJPeBdPQAwEhD/AzFAX34pYc/ngXsJjMEwkrWgkLyAh/igksAwX7wkCEEnCI+ZlzcgATxwl4kpJarpkgBwl4giA41JAXh5l+sHjAjgcOqHl7gweb5pCCh3eYrYDB+AKfqgk77Qk9xjHpZZNA/nnE1ZAbCVl8AynfOFF9epJj3gbM6ZI6rlWM9pC5ZmQSwIAABXksZwRPxwlL0AiGO4Kc3ZKipAAVUXAzwgA3wIffeZnzTwmDRAASpQAoIgm+FJiVPIA1MYnrWQN4OBkGmEjaugmbzAXfxQl7swcrClAmMZnzHwfJbjJbBFA2MngtBXIXgSdGjnMHIUA1VXgI2loLQAVjVZEhc5ChK6/wvw1Q+eiRw/BkgOWAiVxG5DCQ0O5g/IyRtp8xPtaJ5BOJzOwGL/wJ67EZNLmk3GaJPQUFwCIXNi2KVe+qVgKoaNtZP6kBEEZWgPYEYMMAHGN6TQUFQDoYphOqd0aoYjuIaOtQ+wSFL7eH0jFXfoeQxlxRse2Idd+XxBl5UuaYLxAFRU8VUdQACPGqjHgFj34ViqRYYkylpiWY3qAFbXRgh3o21CeWjWcFomclyp1ZV7mSMskIDhIFgNQFiGUD7mc3+UegwawIRKEgOpRQMi2APpRwFkSg3pyHmC8AA78aNOCg1/Iye9OICUSIKuuA3YGHmPA4dYGg11AomTclxj6P+h6XcDsPoM+6MIqfc4rNes0ABO7BIDfYhrwLhYdFqvYriSRAR8aDSL+poKN/oLCnUxegiW9lqw+OoKK7E/K2gI1qcTpdpx2ZBSPagK51kI7wcB8ceuzoqSEzsnVVoIDPgT5Wmq2YCTHUsKEKgIDACXnHBdL7F5SKgNRXmyopCCbrmwhXCuoiBaZhF7MZsNc0mzovCDsWgIyTgKJgF+xAdF+2c928CZQisKhogIFcsJAfAZ+Ze1ZtG0/UcNxRm1sGBGCjuylvAWGaG100MXNaqrHAm2quCb2qoJIgFBAsQWGEiD2EChbqsK4wkBZFsJkRdWAhACHhCDG4S315Cje4v/Cgw6qZ+wPkaoYOKztsdQpIubCQqbueUpo/06J5RrDFB6uZeQZjgnCD16tX+rCv9KDFoquqWQpC6Rq80Ap657CcGpYFRKC6s7DINau5VwcwGVETIpu81gqb5bCUf3Q7D4Eyyrup97DKh6vJOgdYaAE73jAA8bl9+wq9KLggLXdn/Er8RLnGnSvZIAeNsIpJu4P8LpptrQreYbCcgqeGnWuaWwu8XgrvH7CIIVOYdgceq1rdoQsPvLCMtbjL+Av8UgsQW8CA/AATNhvxqLDZrUwCpbSTTRpwn5vMpgshZMv0LWvLagwMUwsx9MCB3QpojAAP4rwNsQtCc8FQ8AwBCK/xTrNr8RysHKALUxzF6EhwiPqsOWQMLF8LUxvCse8FucmGkWUVK6K8TJoJ5HPAhxawgN0Dk0kYHuCA56e8QzgTaIYBmANqPu6w2KG8MKkLRXzLBLgZAQWw6WO8X4U7oXKMYa/MbkELonnMY00bCEUE09wWoTzA2tG8NfrMIqsRlBNL7TQLsnXMUSYUHFSFISfL9QrAy9+8E6awhAWRl3rL3mYLwn7MYAQFCaWBUdgMOgXA7R+8EJuz/l2TyZecnLwL2G3KSEsKZjy8heW75TnAiR9MNbPA7w6w4iEAGQSAIR8JCdZigg4MtZBM33oMTt227ZW8bioL/tkAClaEQFIP/Nh/DNfsM6jcDNhWDOlCDOmqDOvlC1gzABqYvH50DA68DNBUACI1AA6hwBG5AAIQcAA5AApJgmH0DOoyjQIkACKJAA/rwx6CwIl1IAAxABETAAIvAB/8LPDQ0AGu1pflMAukgC3jgCCy0CI+DPgpABAW2KADDSz8w6HwDSu9gLAKxVtepVsMzL1XACIBABAkkO3KwBILABGiDO+bwBINDNSb0BAyDO5hwBBXACAT3RCWAgzogyBUAIH4AB31zQBcDVA3DUSw3Qq8PNH5DUd3jM+szNGJCLBaAyXXiSBaDW38zVZ/3VCcDMvEBo9EtiLiwOB43XA/ABeg0O3GwCXO3/bWkSjwPwjVnd1oLg1Fkdj8nsNwst2eec1QBdANrD2I4NALe4AScg0QCwz6T91BItAt9s1RNN2vnMOuzcC7+VsJAXRKmcrBTRwhpozCMwAEQd1UyNzOHAzdaxkZLd2I1d2uWL2Q8NAEnd05hNCOjc1EjEzcjNOl1oAt4G2+UL1ayD2q1d1Y1N0aTt3coNDLWkwmlKAGuKyJdARbLns4j7DhFgAs+MAXcIAibQttZgzgkN1WnibRsQASSN1SMQ02lizt72jI3NzQce3YPg4CJA3YIg4ASOAqV9REkN20ekzKed1eaN3xhtAhhd3qQN0sJN09pUpf8UVtdcCT2xepax/7QpxrW0/MIVLdogzdQjUNjO8NAALgiO3c0iUNTcnOCa7dgKRxvfDOE0lNgULuRF3c0x3eSs09Rzbd7gDQAiEI8gPQLmbd5Y7uOhxWpmhMgYKKmknAkb9H1bWz1diw8XHdBcLdDXfed4nud3DgKn2DSVVE2VcWKiCsGkCgoW6Obz7Q8ZUN963uiOPgAYsAE/vS8LOxNprMG2WhiSewlMJwgW6Ee7vRsZsAFhlzXh8xO/B5zLGs+UsBOW9BSGO4NqKx2XkgDeWjL6qGahKhGjMGJMEbk/ixxgF3q28MyGYOwNYTsj9QDrJngQoNt/jRq1fuu0UNCRXb7N/QhRfg8hgf8VIbGkByzow8wbw94KAzAu3vgvvU0C1h7TIe3gG7ABywaPHj3OglDQJMDNKMCr997PtIbvJvCFJpAALM3lC70BKlOHBK8yCIfQALDu47wxaFLvgz3hzPDAEazTRhEB80bmoRCPjNjNXYjVzo3XIhDUo40pYl0AhoLO3FzkUR1OQl6K3xgBbF0AEfDc8TgCESLVKLABPW8gvhLXXcjuPgfZOu9zX63Py8AAGDy4Gp8VTU3OqBDT8Dja1oHh6KzO6DzaHVIAGzPyLp/V2y4IkA3aLgf2Zo+S1iHvIK3fGaDaQh2Oqm0o+RyOAKnarNPWjS3OUd0MMxHCTzwg8oZ4pxD/IUkd06TIKluP7ZptzmNP8iRf9ucd4Zpd+UadAFyNkie9+WFO2qRIil8o042tMrGdDCmchQ4y9agw2hiA1Wq/9R0e+dt91F+P1Fy92RNNCPG43wP+0Dvf1PuNAmCO36NY/K/f1vw81w+/1oLA2BFg7aePDOvd3lGPFie/kaYg4ADA/ZI/5pHv3Fwt6Vxe1Dre0uZPCBlghyCd75c/6l9tKCQw2lGd0PSPePIG0rxa1EwICBkoGAUYAwAFCQCLjI2Oj5CRkpOUlBMCAgYhE5WdnpUBAZ+jpKWmp6ipqpImGCAZq7Gys7S1tqkCHQQGAQS3p6G/wsPExZQkCRoRxszN/87PnwIcuwSc0JHB19rb3I2tr93h4uOeIQ4ODQIK5Nnk7u+yyMrw9PXQD5cOC+7t9v7/kkZg2AALoMGDCD/1S8gQXoYNhgZInEixosWLA0ZEENGwo0daCz+K3DYCBMaTKCUmSEAoUQKTJiIsG0mzJqOQNnN+zCBT4oYEJwoUOJFgg0SZBXUqpYdzqVORMk0MALFSKIaVKbNq3cq164CZT581DUuWpogII7yqXcsWI9iyxsbCnUu3rt1Ocu/q3cv3ad6+gAMLRvh3sOHDiLkVTsy4seNaix9LnkwZlKjKmDNrlhR5s+fPgTuDHk16rujSqFPnPK26tWuGrF/Lns30Mv/t27gJ287Nu/e72L6DC58FfLjx46SKI1/OHJLy5tCZP49OvfUDBQEUPOC8u7r34xAEEBAAgfv388Y5COB0icMiXqFCESAQv779+/jz69/Pv7///wAGKOCABBZo4IEIJqggfgZMFoAAojx4GXzxzbfghRhaiOGGB2rI4YcDegjiiP3R5yCEAEiITXc6TVdbWC7CE+NTHQiwzwK5rAgjizbN+BuPNfm4lAcCNGBAOh7o6BeQNAnJDpMjOamUAuk0sI6STkkZjpZbQikSl3aBqZiXH4m5jZnXoAmXmtCw6Yybb5LpEZxPGdBgnXcuZWdYezrVJ3qABirooIQWauihiCb/quiijDZqynXZbacUAx1E6hSkcjIEqXs5GcAAIx5U2oGkm4U3XnlKYYKJL5M6IF4DSj0QXnj70MTAg6wCMB4mqGqmHnvSTAkAkQIslc6nS9W4D5I07ZorBw88kE6emKmoolIG4JgpQgwUmY41q9moayY1GSDeI8xqZi2KU45Xa6fkGRDelTYRS4Cr1H5kbq6LKOuZvzh28NR4+Y7UrS/X5nQrlcWWey4jOIbwGZFGpmuTvAHgKECSOqXDQXgFj6SAAZe8KxKl8W53SQOhhDwZw1Yq5UF4RXKqEwPhOUBvTpiwbNOumDSoKibbOmr00UgnrfTSTDft9NNQRy311FRX/2311VhnrfXWXHft9ddghy322GSXbfbZaKet9tpst+12YnZKyoABHJPCAAE7k/JACASYzMAEeD9y9zoL8Pu20ZgITOy2DzZobtGOhGDjzg04EEDBj497eNI9A6DxZbpMwGl2uoTwgAfjhTCyjYVfxgDfE+QduntHQli3AkWK8kDhIXya+XiLvN73dgEofjkAHARQ9yLYMS8KdgYQYPrmvRUpDToo4rhAewDwmk7v6UCwgLniuaoAkRAEsEkj2rengKsEIOu5AA74AoHl93vwe7EeOJC+/wC4xHXWA4D7PQJ4mksdjsBFvduIZwLnUBEAH0DAc1EQYeTKnHoC0K0GLP9gVI2YIAER2IhzdWsf6unA/gBQI/fgiAG448AEwkNBianKFwgEHgLD08DciEc9C1DRw841RAw6DkUavBd5Ssiqc5GQEefK3ONW2LgUZYJIOMKd5Ghnp0/lsFhf7CFuovgAFbXnQQIrohUvJ0UIaYIDBjhHI86Yoycu4mHoIJkA5oYi4HVrAkdywCJyNi4BkIoRl5jAAlw1LgPUiIFifM3D1ggAfNCvVmr0wLfaqDyaQUB+lcxHrezYPVbhrEjrWCEAGPbJfhHwkZBgwLd4OJ50EOCQkcxlJ0ipy15Sgpe+DKYwh0nMYhrzmMhMpjKXycxmOvOZ0IymNKdJzWpa85oZ2MymNrfJzW5685vgDKc4x0nOcprznK8JBAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 192 patients with refractory angina, the survival free of a cardiac event (acute myocardial infarction, unstable angina, or class IV angina) was better with transmyocardial laser revascularization (TMLR) compared to continued medical therapy (66 versus 11 percent, p &lt;0.001); this was primarily due to a lower incidence of unstable angina (2 versus 69 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Frazier OH, March RJ, Horvath KA. N Engl J Med 1999; 341:1021.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13998=[""].join("\n");
var outline_f13_42_13998=null;
var title_f13_42_13999="Cotton wool spots";
var content_f13_42_13999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cotton wool spots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cotton wool spots are indicative of retinal ischemia. The differential diagnosis includes diabetes, hypertension, AIDS, and the retinal vascular changes of systemic lupus erythematosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_42_13999=[""].join("\n");
var outline_f13_42_13999=null;
